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Abstract 
Acute brain injury (ABI), including cerebral vascular accidents (CVA) and traumatic brain 
injury (TBI), are relatively common diseases which may lead to death, significant morbidity 
and place a heaving burden on health care systems globally, both in suffering and cost. 
Evidence has emerged from basic science research that ketones (beta-hydroxybutyrate and 
acetoacetate) which are water-soluble molecules produced by the liver during times of 
starvation, may have neuroprotective effects. It is therefore theoretically possible that 
increasing plasma ketone concentrations via intravenous or oral supplementation, may lead 
to improved outcomes following ABI.  
This thesis documents a systematic investigation into the possibility that ketone 
supplementation may lead to benefits in patients with a variety of chronic and acute 
neurological conditions. While the main emphasis is on ABI, other conditions where ketones 
may be useful are also reviewed. Beginning with a review of ketones, their potential 
mechanisms of action and likely neuroprotective roles in disease, this thesis examines the 
effects of a novel hypertonic intravenous ketone solution on plasma, cerebrospinal fluid 
(CSF) and brain ketone concentrations in animals, then looks at the hurdles in producing 
such an intravenous solution as opposed to enteral formulations for humans, before 
investigating baseline ketone concentrations in patients with ABI and finally culminating in 
an interventional study where a modified enteral ketone supplement is administered to 
patients with ABI to determine whether adequate plasma ketone concentrations are 
attainable.  
The animal study performed in rats involved the administration of hypertonic saline/ketone 
solutions of varying concentrations to anaesthetised rats. The results demonstrated that 
both CSF and beta-hydroxybutyrate (BHB) concentrations increased over time (p<0.0001) 
and that this was dependent on the BHB concentration in the solution (p<0.0001). 
Measurement of BHB concentrations in brain tissue noted a dose dependent increase 
compared to control with the highest concentration almost double 0.15 mmol/l versus 0.28 
mmol/l. Significantly, the infusions did not lead to a metabolic acidosis which has been a 
concern amongst researchers.  
These findings led to an attempt to produce an intravenous solution for administration to 
humans. However, the cost of producing this formulation proved prohibitive. Another source 
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of ketones was therefore sort. While this was underway, as baseline data was lacking, we 
undertook a study to measure ketone concentrations in patients with ABI.  
The subsequent study recruited 38 patients with ABI and followed them for up to 7 days. 
Both plasma and CSF (where possible) concentrations of BHB and Acetoacetate were 
measured on a daily basis. 22 patients completed the full 7 days of observations, 7 CVA, 7 
subarachnoid haemorrhage (SAH) and 8 TBI. During the study period, BHB concentrations 
increased initially but normalized by day 3 while acetoacetate (AcAc) concentrations 
remained within the normal range. There was a weak correlation between blood and CSF 
BHB (Spearman’s rho = 0.62, P=0.054). It was therefore clear that as blood ketone 
concentrations remained low, an external source would be required to increase blood ketone 
concentrations to clinically relevant concentrations.  
Therefore, a study investigating enteral based supplementation with the view to increasing 
ketone concentrations in ABI patients was designed. The study was to look at the feasibility 
of administering a ketogenic enteral formulation to patients with ABI over a 6 day period. 
Outcomes included ketone concentrations in blood and CSF (where possible) and 
monitoring for adverse events resulting from the ketone administration. It was determined 
that the commercially available product Ketocal (Nutricia) would be the most suitable enteral 
supplement. However, as this product was lacking in sufficient protein, a protein supplement 
was added. The study was entitled “Induction of ketogenesis in patients with acute brain 
injury via oral administration of a ketogenic feed” or KABI and intended to recruit 20 patients.  
While the KABI study was under development, 2 further reviews were undertaken in order 
to further examine the current literature on cerebral nutrition and the place of ketogenesis in 
this process. The first reviewed the place of metabolic substrates other than glucose on 
cerebral energetics. These included ketones, lactate, non-esterified fatty acids, branch-
chain amino acids, and TCA cycle intermediates including triheptanoin. It was noted that 
while glucose is the main substrate for the brain in health, other metabolic substrates may 
prove beneficial in the injured brain. While ketones have received the most in-depth study 
and appear to be an excellent substitute for glucose, exploration into the field of cerebral 
energetics is in its infancy and further research is necessary.  
The second was a systematic review of publications focusing on the use of ketones in both 
acute and chronic neurological disorders in adults (excluding chronic poorly controlled 
epilepsy). As expected, the data is very limited, consisting of mainly case series and small 
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randomised controlled trials. Study subjects included Alzheimer’s disease, severe refractory 
status epilepticus, intracranial neoplasms, TBI and Parkinson’s disease. Although outcomes 
were largely positive, the poor quality of the evidence prohibits firm recommendations other 
than that further research is necessary to explore the potential benefits of ketones in a 
number of neurological conditions.  
The KABI study was subsequently undertaken and completed. We recruited 20 patients, 5 
females and 15 males, 3 with stroke, 2 with subarachnoid haemorrhage and 15 with 
traumatic brain injury. We were able to demonstrate a significant increase in both plasma 
beta-hydroxybutyrate and acetoacetate to 0.61 ± 0.53 mmol/l (p =0.0005) and 0.52 ± 0.40 
mmol/l (p<0.0001) over the 6 day period. The total daily Ketocal® caloric intake was 
positively correlated with plasma beta-hydroxybutyrate concentrations (p=0.0011). The 
feeds were well tolerated in 19 out of the 20 patients with no clinically significant changes in 
acid/base status over the 6 days with pH remaining within normal range. One patient 
developed a metabolic acidosis and feeds were ceased. We concluded that in patients with 
acute brain injury, although an enterally administered ketogenic formulation was well 
tolerated more work was required to determine the optimal concentration of ketones 
necessary to impact on cellular energetics and the best means of inducing ketosis. 
One of the main issues limiting progress in investigating ketones as a therapeutic tool is the 
difficulty in attaining high plasma ketone concentrations rapidly and consistently using the 
current enteral approach. The ketone monoester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate, 
may provide a solution to this problem. The thesis concludes by highlighting gaps in 
knowledge, challenges and avenues for future research. 
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Preamble – Scope of Thesis 
This thesis documents my interest in the subject of cerebral energetics which initially began 
with discussions with Professor Venkatesh in 2008. Having always considered (as most 
doctors) ketones to be bad, I was surprised to discover the many potential therapeutic 
benefits provided by this small molecule. The published literature at that stage was sparse 
but suggested that energy provided by ketones could readily be used by the brain as a 
substitute for glucose, especially in the circumstances of brain injury. Given the poor 
outcomes from brain injury and the paucity of positive interventions, it seemed to me that 
ketones could provide a long sought-after therapeutic modality. The chapters that follow 
represent the state of the art knowledge of ketone therapeutics at this time.  
This thesis covers the period from 2009 to 2018 and includes clinical and animal studies 
completed in an attempt to produce an intravenous and enteral ketone formulation suitable 
for patients with ABI. These studies include a hypertonic BHB saline solution administered 
to animals (chapter 2), an observational study examining ketone concentrations in adult ABI 
patients (chapter 4) and an interventional study investigating the effects of a ketogenic 
enteral feed in adults with ABI (chapter 7). 
Ketones, which are naturally produced in times of starvation, represent a potential source of 
energy to the injured brain.  
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Chapter 1:  The Role of Ketones in Brain Injury 
1.1.    Synopsis and Citation 
Aim:  
This chapter explores the physiology of ketone body utilization by the brain in health and a 
variety of neurological conditions and further discusses the potential for ketone 
supplementation as a therapeutic option in traumatic brain injury.  
Citation:  
This chapter is based on a publication reviewing the use of ketone supplementation in 
traumatic brain injury. Figures and tables have been inserted into the text at different 
positions and the numbering of pages, figures and tables has been adjusted to fit the thesis. 
The references have been incorporated with the other references of the Thesis.  
The original manuscript was: 
White H, Venkatesh B.  Clinical review: ketones and brain injury.  Crit Care. 2011; 15:219. 
Professor Venkatesh assisted with preparation of and co-authored the original manuscript 
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1.2.    Introduction 
Ketogenesis is the process by which ketone bodies, during times of starvation, are produced 
via fatty acid metabolism. Although much feared by physicians, mild ketosis can have 
therapeutic potential in a variety of disparate disease states. The principal ketones include 
acetoacetate (AcAc), β-hydroxybutyrate (BHB) and acetone. In times of starvation and low 
insulin concentrations, ketones supply up to 50% of basal energy requirements for most 
tissues, and up to 70% for the brain. Although glucose is the main metabolic substrate for 
neurons, ketones are capable of fulfilling the energy requirements of the brain. The purpose 
of this review is to explore the physiology of ketone body utilization by the brain in health 
and a variety of neurological conditions and to discuss the potential for ketone 
supplementation as a therapeutic option in traumatic brain injury. 
1.3.    Ketones, metabolism and the brain 
Ketone metabolism 
Ketones are by-products of fat metabolism and are produced in hepatic mitochondria1.  More 
specifically, the three ketone bodies (KB) are (see Figure 1.1); 
• Acetoacetate (AcAc) - if not oxidized to form usable energy, is the source of the two 
other ketone bodies below. 
• Acetone - is not an energy source, but is instead exhaled or excreted as waste. 
• β-hydroxybutyrate (BHB) - is not technically a ketone but is reversibly produced from 
acetoacetate 
 
Figure 1.1 Chemical structure of ketone bodies 
Reprinted by permission from Elsevier Publishers Ltd: Metabolism. Bouteldja et al 63(11):1375-1384, copyright 
2014 
The Role of Ketones in Brain Injury 
3 
The precursor for the synthesis of ketones is acetyl CoA, which is formed by ß-oxidation of 
free fatty acids in the liver (although the potential for extrahepatic ketone production is still 
under investigation)2. The two important determinants of ketogenesis are availability of 
acetyl CoA and mobilization of fatty acids liberated from white adipose tissue during fasting 
or catecholaminergic stress 3, 4.  
Acetoacetate is the central ketone body. It is reduced to BHB by BHB dehydrogenase (BHD) 
in a NADH-requiring reversible reaction 4;  
(R)-3-hydroxybutyrate + NAD+ ↔ acetoacetate + NADH + H+   
The extent of this reaction depends on the state of the cellular pool of NAD+ 5.  When highly 
reduced, most or all ketones will be in the form of BHB. The ratio of AcAc to BHB reflects 
the redox state within the mitochondrial matrix 6. BHB is non-volatile and is chemically stable. 
Its only metabolic fate is interconversion with AcAc. Once synthesized, ketones diffuse into 
the circulation.  
 
Figure 1.2 Fate of circulating ketones during fasting 
Prolonged fasting with subsequent inhibition of insulin release results in increased circulating free fatty acids 
(FFAs) which serve as substrate for ketogenesis in the hepatocytes. Ketone bodies are released into 
circulation and subsequently taken up by brain cells. As glucose levels are low, ketones bodies may provide 
up to 2/3 of cerebral energy requirements. 
The Role of Ketones in Brain Injury 
4 
Reprinted by permission from Elsevier Publishers Ltd: Metabolism. Bouteldja et al 63(11):1375-1384, copyright 
2014 
Fate of circulating ketones 
Plasma concentrations of circulating ketone bodies range from < 0.1 mmol/l in the post 
prandial state to as much as 6 mmol/l during fasting with concentrations reaching 25 mmol/l 
in diabetic keto-acidosis 7-9. Under normal dietary conditions, ketogenesis from fatty acids is 
at very low concentrations. This is attributable to the relatively high blood concentrations of 
the ketogenesis-inhibiting hormone insulin, and low blood concentrations of ketogenesis-
promoting hormones, glucagon and cortisol 3. Therefore, one of the prerequisites for 
ketogenesis is low concentrations of circulating insulin as seen during starvation and 
diabetic ketoacidosis. 
During periods of low insulin, catabolic hormones such as glucagon, cortisol, 
catecholamines, thyroid hormone and growth hormone increase and induce ketogenesis via 
stimulation of lipolysis of FFA and subsequent stimulation of β-oxidation in the liver. The 
principle regulators for this cellular response are the Peroxisome Proliferator Activated 
Receptors (PPARs). These transcription factors are modulated directly by FFA’s 10.  In the 
brain, astrocytes, which are capable of producing ketone bodies (see below), are also 
regulated by PPARs 11. Aside from the ketogenic properties, activation of PPARs have been 
shown to produce anti-inflammatory and anti-oxidant effects independently which may prove 
to have neuroprotective properties 12, 13 
The majority of circulating ketone bodies will be taken up by extrahepatic tissues, although 
10–20% may be lost in the urine 9, 14. KB’s provide an energy source for several tissues 
including brain, skeletal muscle, myocardium and liver although heart and kidney have the 
greatest capacity for utilization 15. The rate of utilization appears to be a function of the 
circulating plasma concentrations16-18. 
Ketones and Critical Illness 
The major illness associated by intensive care physicians with ketosis is diabetic 
ketoacidosis (DKA).  Outside of DKA, ketone measurement is not routinely performed and 
has been largely used as a research tool to quantify cellular redox status. The arterial ketone 
body ratio (AKBR) is utilized to reflect the ‘mitochondrial redox status’ of hepatic cells and 
may reflect cellular energy status in a number of conditions including hemorrhage, hypoxia, 
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sepsis and hepatic resection 19. The AKBR (ratio of acetoacetate to β-hydroxybutyrate) 
reflects the cellular NAD+/NADH ratio, which cannot be measured directly and is linked to 
the phosphorylation potential of the cell (see equation above). In critically ill patients the 
redox state of cellular mitochondria is further reduced inhibiting the entry of acetyl CoA into 
the tricarboxylic acid cycle (TCA). Consequently, acetyl CoA combines with another 
molecule of acetyl CoA to form acetoacetic acid, which in turn is converted to β-
hydroxybutyrate leading to an altered NAD+/NADH ratio and decreased AKBR 19, 20. 
Therefore, a reduced AKBR is a sign of an inefficient TCA cycle.  The AKBR has also been 
used as an indirect marker of the hepatocellular functional status as the predominant site of 
metabolism of the ketones is in the liver. 
Not surprisingly, metabolic failure at the cellular level is associated with worse clinical 
outcomes. A low AKBR is associated with poor outcomes in both animal and human models 
of illness. Yassen et al measured AKBR in 20 critically ill patients 20. They demonstrated a 
progressive decrease in those patients with septic shock who died. In a study of critically ill 
heart failure patients, Limuro et al noted a survival of only 15% of patients with an AKBR of 
< 0.7 21. Dresing found AKBR’s to be significantly lower in non-survivors than survivors in 
30 polytrauma patients (0.6 vs 1.3; p=0.001) 22. However, Levy et al failed to find a difference 
in AKBR levels between survivors and non-survivors in their cohort of septic patients 23. In 
conjunction with the lactate: pyruvate ratio, AKBR may provide further insight into the cellular 
redox potential of critically ill patients. 
Ketones and the heart 
Although the ability of heart muscle to utilize ketones as an energy substrate has been 
known for some time, only recently have the potential benefits of ketone supplementation in 
heart failure been explored. Animal research has demonstrated that the expression of the 
enzyme β-hydroxybutyrate dehydrogenase 1 is increased in heart failure suggesting a shift 
to ketone metabolism 24. Whether this is adaptive, or maladaptive is not known at this stage. 
Some early studies found that when ketones were utilized as the sole substrate, cardiac 
function actually decreased in an isolated rat heart model 25. This was thought to result from 
interference by ketones in several downstream intermediates of the Kreb cycle, a process 
which could be reversed by anaplerosis. Further research is required to better clarify the 
role of ketones in the failing heart.  
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Ketones and the brain 
Glucose is the major fuel for the brain in humans on a balanced diet. More recently it was 
proposed that other substances such as lactate and pyruvate may be utilized by neurons to 
sustain their activity 26. Furthermore, during times of starvation, the brain has the capacity 
to adapt to the use of ketones as its major energy source (and in the metabolic disease 
diabetes mellitus). In starvation of long standing, ketones can provide 60 - 70% of the energy 
needs of the brain 27. The 1.5 kg human brain utilizes 100–150 g of glucose per day and 
20% of the total body oxygen consumption at rest 8. Protein catabolism can supply 
somewhere between 17 and 32 g of glucose per day, well below the minimum daily cerebral 
glucose requirements 28. In fact, to supply sufficient glucose to support brain metabolic 
requirements from protein alone would lead to death in about 10 days instead of the 57–73 
days 29. Moreover, in subjects undergoing total starvation for 30 days, the decrease in 
hunger coincides with the elevation of blood ketones to 7 mmol/l. During periods of ongoing 
starvation, an average size person produces about 150 g of ketone bodies per day 30. It 
should be noted however that ketones are incapable of maintaining or restoring normal 
cerebral function in the complete absence of glucose. 
Astrocytes may play a significant role in the regulation of brain energy metabolism 31. 
Reports suggest that astrocytes can produce ketone bodies from fatty acids and leucine and 
are involved with other pathways of lipid metabolism, such as lipid synthesis and lipoprotein 
secretion 32-35. Furthermore, it appears that the production of lactate and ketone bodies by 
astrocytes may increase secondary to neurotransmitters released during enhance synaptic 
activity 36, 37. Neurons, astrocytes and oligodendrocytes are all capable of utilizing ketones 
as a substrate 38. 
Although the implications of ketone body production by astrocytes are still unclear, the fact 
that astrocytes outnumber neurons approximately nine to one and occupy at least 50% of 
the cerebral volume suggests this constitutes a quantitatively important pathway in the 
brain 39. 
Regulation of cerebral ketone uptake 
As previously noted, humans can achieve very high circulating KB concentrations during 
prolonged fasting, up to 9 mmol/l (range 5.8-9.7) 27. The plasma concentration of KBs is a 
significant factor affecting the rate of cerebral uptake. The blood brain barrier (BBB) is 
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relatively impermeable to most hydrophilic substances, such as KBs, unless they are 
transported by a carrier protein. A family of proteins involved in the transport of 
monocarboxylic acids such as lactic acid and pyruvate across cellular membranes called 
monocarboxylic acid transporters (MCT1 and 2) are thought to play an integral role.  
It is not yet understood how MCT’s are regulated. KBs are transported at different rates with 
the uptake of acetoacetate being twice that of BHB at a given arterial concentration 17. 
Furthermore, prolonged fasting appears to increase the BBB uptake of ketones with some 
researchers demonstrating an 8-fold increase in the expression of MCT1 40. Similarly, 
Hasselbalch et al reported a 13-fold increase in cerebral uptake of BHB in humans following 
several days of fasting 41. In contrast, rapidly increasing plasma ketone concentrations does 
not lead to as significant an increase in cerebral ketone uptake. Pan et al noted a much 
smaller increase in cerebral ketone concentrations following a rapid intravenous infusion of 
BHB as compared to prolonged fasting implying that MCT upregulation is partly dependent 
on length of exposure to increased plasma ketone concentrations 42, 43. Animal studies have 
demonstrated an age related difference in MCT 1 expression with a switch from fatty acids 
and ketones preference in the young to carbohydrates metabolism with aging 44, 45. 
Once across the BBB, KBs enter brain cells to support cellular energy requirements. Studies 
of the uptake of KBs by brain cells suggest entry occurs by two mechanisms: diffusion and 
a carrier-mediated process. MCTs have been demonstrated on neurons and glial cells 
although their role here appears less significant as compared to on the BBB. The impact of 
mitochondrial enzyme activity involved in ketone metabolism is less clear. Certainly, 
mitochondrial enzymes can be upregulated by increased concentrations of BHB as has been 
demonstrated following exposure to ketones through starvation or prolonged high fat diet 17, 
46, 47.  In summary therefore, a prolonged high blood ketone concentration leads to an 
increased rate of cerebral ketone uptake and metabolism.  
Regional variation in KB metabolism 
Data for this are based largely on animal studies. Hawkins et al noted that KB uptake varies 
from one brain region to another 48, 49. Following an intravenous administration of radioactive 
BHB to adult rats, uptake was greatest in the cerebral cortex (deep layers), the superior and 
inferior colliculi and regions where the BBB is absent 48, 49. Areas with a low metabolic rate 
such as the corpus callosum and other white-matter structures demonstrated much reduced 
uptake. Interestingly, the pattern of KB uptake resembled that of glucose except in the 
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superficial layers of the cortex where glucose uptake was higher 50. Similarly, MCT1 
expression in the brain may resemble the pattern of KB uptake with some exceptions as 
MCT1 is found on glia and neurons as well as on BBB epithelial cells and because the 
pituitary and pineal have no BBB.  
Neuroprotective effects of ketones 
Neuroprotection is the mechanisms and strategies that once implemented, may lead to 
salvage, recovery or regeneration of the nervous system. Ketones may have a 
neuroprotective effect (see Figure 1.3). Ketones represent an alternative fuel for both the 
normal and the injured brain 51. Firstly, β-hydroxybutyrate is more energy efficient than 
glucose and can stimulate mitochondrial biogenesis via the upregulation of genes encoding 
energy metabolism and mitochondrial enzymes 52. 
 
 
Figure 1.3 Potential neuroprotective mechanisms of ketones 
Ketones (1) require only three enzymatic steps to enter the TCA cycle; (2) reduce the NAD couple; (3) decrease 
free radical formation; (4) increase production of ATP; (5) increase mitochondrial uncoupling; (6) increase 
glutathione peroxidase activity; and (7) inhibit pyruvate entry into the TCA cycle. 
Reprinted by permission from Macmillan Publishers Ltd: J Cereb Blood Flow Metab. Prins 28(1):1-16, copyright 
2008 
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There is a marked increase in free energy of ATP hydrolysis as demonstrated by a 25% 
increase in hydraulic work of isolated rat perfused heart preparations when exposed to KB 
53. Also, ketones increase the intermediary metabolites delivered to the citric acid cycle with 
a 16 fold elevation in acetyl CoA content. Secondly, ketones protect against glutamate 
mediated apoptosis and necrosis through the attenuation of the formation of reactive oxidant 
species. Ketones can oxidize co-enzyme Q thus decreasing mitochondrial free radical 
formation. Additionally, the reduction of NAD favors reduction of glutathione, which 
ultimately favors destruction of H2O2 by glutathione peroxidase reaction 54, 55. Thirdly, 
ketones enhance the conversion of glutamate to gamma-aminobutyric acid (GABA) with the 
subsequence enhancement of GABA-mediated inhibition 56, 57. Cerebral ketone uptake also 
increases cerebral blood flow (CBF) 58. Fourthly, cell death from apoptosis is attenuated by 
ketone ingestion 56. Mechanisms include reductions in activation of caspase-3, increases in 
calbindin and prevention of accumulation of the protein clusterin. Lastly, cerebral ketone 
metabolism alters cerebral blood flow (CBF) 58. Hasselbalch et al demonstrated a 39% 
increase in CBF following an infusion of NaBHB. 
More recently, Greco et al demonstrated that the initial neuroprotective effects of BHB are 
secondary to the antioxidant properties while later benefits are related to substrate 
augmentation 59. There are also age related variations in ketone uptake and utilization which 
require further study. Furthermore, evidence suggests that not all effects of ketones are anti-
inflammatory in nature and may depend on cell type, ketone concentration and other 
comodulators 2.  Specifically, AcAc in certain circumstances appears to activate pro-
inflammatory signalling 60. Further research to better delineate the impact of ketones on 
inflammatory pathways is necessary.  
1.4.    Current state of research - Changes in ketone metabolism during brain injury  
Models of Injury - Animal studies 
Adaptive changes to cerebral ketone metabolism during development and starvation are 
well documented. However, there is evidence that other conditions including traumatic brain 
injury (TBI), ischemia, hemorrhagic shock and hypoxia induce rapid changes in both 
vascular and cellular transporters that favour ketone uptake and metabolism. In addition, 
ketone-metabolizing enzymes demonstrate the ability to change in response to 
neuropathologic conditions. Collectively, these adaptations suggest that the brain may be 
more receptive to ketone metabolism under neuropathic conditions. 
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Researchers have demonstrated an increase in MCT1 and MCT2 expression following 
cerebral injury 61. Similarly, ketone metabolizing enzymes expression also appears to alter. 
Utilization of BHB in the brain is contingent on its conversion to acetoacetate by β-
hydroxybutyrate dehydrogenase, which is scarce in the adult brain, especially in the basal 
ganglia. Studies confirm a significant increase in BHD activity following cerebral insult. 62  
The brain’s ability to utilize exogenous ketone bodies is altered. At times of oxidative stress, 
the ability of the brain to use glucose as a substrate for metabolic activity may become 
compromised. Certainly, hyperglycemia has been repeatedly shown to be deleterious to the 
injured brain 63. During these times, an exogenous supply of ketones may force the brain to 
shift its reliance from glucose to ketones, thus taking advantage of improved transport and 
cellular metabolism. This has proven to be advantageous in both acute brain injury models 
(glutamate excitotoxicity, hypoxia/ischemia, TBI) and neurodegenerative conditions 
(Parkinson’s disease, Alzheimer’s disease). 
Ketone supplementation has been investigated in a number of models of cerebral injury 
including glutamate toxicity, hypoxia/ischemia injury and traumatic brain injury. Glutamate 
neurotoxicity is implicated in a number of neurodegenerative disorders associated with brain 
ischemia, hypoglycemia and cerebral trauma. During injury glutamate and aspartate are 
released through the reverse action of their transport systems or via enhanced exocytotic 
release. This in turn leads to excitotoxicity and the production of reactive oxidant species. 
Administration of ketones appears to limit the extent of damage 64-68. For example, Massieu 
et al demonstrated that acetoacetate effectively protects against glutamate neurotoxicity 
both in vivo and in vitro in rats chronically treated with a glycolysis inhibitor 65.  
Hypoxic/ischemic injury leads to a decrease in oxidative metabolism by reducing oxygen 
availability 69, 70. Ketone administration ameliorates many of the sequelae of this process 
including lactate generation, free radical damage and apoptotic cascade activation 71, 72. 
Suzuki et al demonstrated that BHB prolonged survival time in rat models of hypoxia, anoxia 
and global ischemia 73. They further showed that BHB reduced infarct size after MCA 
occlusion, irrespective of whether BHB administration was delayed.  
More recently, traumatic brain injury models have been developed 74, 75. TBI is associated 
with impaired cerebral energy production with prolonged glucose metabolic depression and 
reduction of ATP. Cerebral injury is further exacerbated by free radical production, and 
activation of poly-ADP-ribose polymerase via DNA damage 76. As such, under these 
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conditions of impaired glycolytic metabolism shifting the brain toward ketone metabolism 
may limit the extent of cerebral injury 73, 77-80 (see Table 1.1). Much of this work is attributable 
to Prins et al who demonstrated that administration of intravenous BHB after TBI in adult 
rats led to an increase in uptake of BHB and alleviated the decrease in ATP after injury. In 
a subsequent study they found that a ketogenic diet was effective in reducing the cortical 
contusion volume in a rat model of TBI 74, 75. Of concern is a recent finding that BHB 
administration to rats with TBI may have detrimental effects on BBB permeability 81. The 
study investigated the effect of BHB on BBB integrity following TBI noting that while nuclear 
factor-kappa B expression decreased, BBB permeability as evidenced by an increase in 
Evans blue extravasation in the ipsilateral cortex was noted. Although the mechanisms are 
unclear, the diverse effects of BHB may be due to its ability to variably change local cerebral 
oxidant/antioxidant capacity. More research is needed to clarify this issue. 
Neurodegenerative conditions may also benefit from ketone administration as there is 
evidence of altered cerebral metabolism. Studies of Parkinson’s and Alzheimer disease 
confirm the encouraging effects of ketones. Mechanisms are complex but include 
decreasing free radical production and providing acetyl-CoA for energy production. 53, 62, 82-
85. Other conditions which may be responsive to ketones include amyotrophic lateral 
sclerosis and certain brain tumors (see Chapter 6). 
Models of injury – human research 
Mild ketosis is induced in humans by either fasting or the consumption of a high fat, low 
carbohydrate diet. Most studies in humans have delivered ketones via the enteral route 86. 
In adults, achieving blood concentrations of 5–7 mmol/l total ketone bodies requires the 
production or intake of about 150 g per day 30. This however is subject to the influences of 
glucose, insulin, cortisol and catecholamines. It has been suggested that to achieve a 
therapeutic response in refractory epilepsy, the concentration of blood ketone should be 
above 4 mmol/l 87.  
Salts of ketone bodies can be produced. Several authors (see below) have administered Na 
AcAc or Na BHB successfully with few side effects. A new formulation called KTX 0101 
consists of a combination of NaCl and BHB although relevant concentrations are not 
described 88. Main issues related to IV administration of ketone solutions include; volume 
loading, Na loading and the potential for significant metabolic alkalosis. This will depend on 
the relevant concentrations of anions and cations in the mixture and the osmolality.  
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Two studies have examined baseline ketone concentrations in humans with TBI. The first 
was an observational study of 38 patients with acute brain injury (ABI) on a normal diet which 
demonstrated that BHB concentrations were raised on admission but normalized rapidly 89.  
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Table 1.1    Animal and basic science studies on effects of ketone administration on brain injury 
Mechanism of injury Reference Ketone 
source 
Study Outcome 
Glutamate induced injury Massieu et al., 
2003 65 
IV  AcAc infusion for 14 days in adult rodent model 
prior to and during glutamate induce injury 
↓ neuronal damage, ↓ lesion volume and ↑  
cellular ATP levels 
 Noh et al., 
2006/2003 67, 68 
PO 21 day old Mice fed ketogenic diet prior to kianic 
induced neuronal damage 
Preservation of neurons in hippocampus 
by inhibiting caspase-3-mediated 
apoptosis 
 Mejia-Toiber et al., 
2006 66 
* BHB applied before glutamate induced neuro-
toxicity. 
BHB reduces injury and lipoperoxidation 
 Maalouf et al., 
2007 64 
* Addition of BHB to invitro model of glutamate 
neurotoxicity 
Reduction in free radical formation and 
enhance mitochondrial respiration 
Cerebral hypoxia Puchowicz et al., 
2005 70 
PO Rats fed ketogenic diet 3 weeks prior to hypoxic 
injury 
Decreased cerebral lactate and increased 
tolerance of hypoxia 
 Masuda et al., 
2005 69 
* Rat neurons exposed to hypoxia following 
treatment with BHB 
Decreased cell death and number of 
apoptotic cells with maintenance of 
mitochondrial membrane 
Cerebral ischemia Suzuki et al., 
2001 80 
IV 
 
Rats infused with BHB 3-6 hours after bilateral 
carotid artery occlusion 
Decreased cerebral oedema and sodium 
content and increased ATP levels 
 Suzuki et al., 
2002 73 
IV BHB infusions following occlusion of Middle 
cerebral artery 
50% reduction in cerebral infarct volume 
 Marie et al., 
1990 79 
Fasted Adult rats fasted for 24 hours before four vessel 
occlusion 
Decreased mortality, post-traumatic 
seizures and brain lactate 
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Mechanism of injury Reference Ketone  
source 
Study Outcome 
 Go et al., 
1988 78 
Fasted Starvation induced ketosis followed by carotid 
occlusion 
Fasting protected rats from brain infarction 
Traumatic brain injury 
 
Prins et al., 
2004 75 
IV BHB infusion following TBI in adult rats Increase in serum BHB and cerebral BHB 
and improved cortical ATP levels 
 Prins et al., 
2005 74 
PO Rats with TBI fed ketogenic diet  
 
50% reduction in cortical contusion volume 
 Biros et al., 
1996 77 
PO Rats of differing ages fed ketogenic diet following 
TBI 
Younger rats demonstrated larger 
reduction in contusion volume 
 Hu et al, 
2009 71, 72 
PO Rats fed ketogenic diet prior to TBI 
 
Reduced brain oedema and cellular 
apoptosis in rats fed ketone diet 
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The second investigated the impact of targeting tight glycemic control on BHB 
concentrations post TBI. They noted an increase in BHB concentrations with improved 
glycemic control although this was in the setting of increased insulin usage and permissive 
underfeeding 90. 
There is a paucity of research examining the effects of ketone administration in humans. 
Interpretation of results is further complicated by variable routes of administration, 
concentrations and age variability of research subjects. For instance, research on the effects 
of intravenous ketone preparations are confined almost exclusively to adults whereas, 
dietary studies include a large number of children. As far as we are aware, only two clinical 
studies examining the neuroprotective effects of KB in humans have been undertaken. The 
first by Ritter et al examined the effects of a ketogenic diet on biochemical markers of 
metabolism in head injury patients but did not include clinical outcomes 91. The second 
reported by Smith et al has never been published but reported on the use of a sodium BHB 
solution for neuroprotection during cardiac surgery 88. The bulk of the research has taken 
place using the rodent model.  
Some general statements however, can be made. It has been demonstrated that; ketones 
can be given enterally or intravenously with minimal side effects, utilization of ketone bodies 
increase with rising blood concentrations, with a plateau at approx. 128g/24 hours, hyper-
ketotic states are associated with improved glucose control, increased plasma 
concentrations lead to increase in cerebral uptake and ketogenic diets may lead to improved 
cognitive function in patients with chronic dementia (see Table 1.2). However, well designed 
outcome studies are lacking 42, 43, 88, 91-98. 
Adverse effects of ketones  
There is minimal data on the adverse effects of ketone administration, much of which is 
based on chronic intake via the enteral, rather than the parenteral route. In the acute setting, 
effects of parenteral formulations on pH, Na, lipids and glucose are likely to dominate e.g. 
IV formulations would theoretically be alkalinising, depending on the ketone concentration. 
This was confirmed by Hiraide et al who noted a significant increase in pH and Na 
concentrations following the IV administration of a 20% solution of NaBHB to severe trauma 
patients 94. Also of potential concern is the reduction in glucose cerebral metabolism and 
increase in CBF demonstrated by Hasselbalch et al during administration of intravenous 
BHB 58. The long term consequences of this are not known.
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Table 1.2    Human studies investigating effects of exogenous ketone administration 
Pathophysiological endpoints Reference Study Outcome 
Metabolic effects Owen et al., 
1973 96 
Effect of ketones on insulin and free fatty 
acid release. Sodium AcAc given as IV 
infusion 1 mmol/kg over 2 hrs to 12 normal 
adults after overnight fast. 
AcAc levels 4.74 mmol/l after 30 min 
Utilization of ketones increased with rising 
blood concentrations to a maximum of 13 g/24 
hr. Glucose remained normal 
 
Miles et al., 
1983 95 
Evaluation of protein sparing effects of  
IV infusion of NaBHB in 6 healthy adults.  
Ketone levels reached 2.33 mmol/l 
No protein sparing, significant alkalosis 
 
Hiraide et al.,  
1991 94] 
20 pts following severe trauma. 11 pts 
received IV 20% solution NaBHB at 25 
umol/kg/min for 3 hrs. 9 pts received Na 
lactate. 
Ketone levels reached 1.5 mmol/l. Alanine 
release decreased in ketone group suggesting 
a suppression of posttraumatic protein 
catabolism. There was a significant increase in 
Na and pH 
 
Dashti et al., 
2007 93 
64 health obese adults with and without 
diabetes fed ketogenic diet for 56 weeks. 
BMI, glucose, total and LDL cholesterol 
decreased significantly whereas HDL 
increased 
CNS effects Pan et al., 
2001 43 
6 healthy adults infused with NaBHB at a 
bolus rate of 80 umol/kg/min, then 20 
umol/kg/min for 75 min. BHB brain levels 
measure by MRI 
 
BHB blood levels reached 2.12 mmol/L 
BHB brain levels increased to 0.24mol/L 
Levels lower then noted in fasted individuals 
suggesting differences in brain transport of 
ketones in fasted state 
 
Pan et al., 
2000 42 
5 healthy adults. Ketones measured in 
brain using MRI in non-fasted state and 
after 2 and 3 day fast. 
Plasma and brain BHB levels correlated well 
with brain ranging from 0.05 mmol/l in 
nonfasted state to 0.98 mmol/l after 3 days 
fasting 
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Pathophysiological endpoints Reference Study Outcome 
 
Blomqvist et al., 
2002 92 
6 healthy and 6 diabetic pts received 
infusion of BHB at 3-6 mg/kg/min for 60 
min followed by bolus of B-[11C] HB. PET 
scan was performed 
Utilization rate of ketones increase 
proportionally with plasma concentrations. 
Rate limiting step for ketone body utilization is 
transport into the brain 
Pathophysiological endpoints Hasselbalch et al., 
1995 98 
Permeability of blood brain barrier to BHB 
was assessed following a 3.5 day fast. 
Increase cerebral ketone influx during 
starvation determined by amount of ketone 
present in blood. 
 
Ritter et al., 
1996 91 
20 head injured patients assigned to 
conventional or ketogenic diet for 2 weeks.  
Group receiving ketogenic diet demonstrated 
improved glucose control with higher ketone 
levels. Cerebral lactate was similar 
 
Smith et al., 
2005 88 
NaBHB IV solution known as KTX 0101 for 
neuroprotection post CABG. Details of 
study protocol not available 
Phase IA study not published  
 
 
Hasselbalch et al.,  
1996 58 
8 healthy adults received IV infusion of 
NaBHB at 4-5 mg/kg/min for 3 hrs. 
Cerebral blood flow measured using Kety-
Schmidt technique 
Increased cerebral uptake of ketones was 
counterbalanced by reduction in glucose 
metabolism. Cerebral metabolic rate was 
unchanged however cerebral blood flow 
increased. 
 
Reger et al., 
2004 97 
20 adults with Alzheimer’s disease were 
randomized to receive a MCT diet or 
placebo on two occasions.  
On cognitive testing, MCT treatment facilitated 
performance for 4- but not 4+ subjects. Also 
greater improvement with MCT treatment 
relative to placebo 
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Some side effects are predictable following enteral administration such as dehydration and 
hypoglycemia. Others are less common and present following prolonged use, including 
growth retardation, obesity, nutrient deficiency, decreased bone density, hepatic failure, and 
immune dysfunction. 
Freeman has reported a significant rise in mean blood cholesterol to over 250 mg/dl 
following prolonged intake a of ketogenic diet. 99. This in turn may be atherogenic, leading 
to lipid deposition in blood vessels. In addition there are reports of dilated cardiomyopathy 
in patients on the ketogenic diet, possibly as a consequence of the toxic effects of elevated 
plasma free fatty acids. Finally, an increased incidence in nephrolithiasis in patients on the 
ketogenic diet as well as increases in serum uric acid secondary have been reported 76, 100. 
1.5.   Potential clinical applications for ketone solutions – traumatic brain injury 
Traumatic brain injury is a major cause of mortality and morbidity in young adults 101. 
Cerebral edema and subsequent intracranial hypertension is an important factor influencing 
patient outcome, and despite considerable research, has proven difficult to manage. Over 
the past 30 years, osmotherapy has become an important tool in the management of 
intracranial hypertension after TBI. 101. Various substances, including urea, glycerol, sorbitol 
and mannitol have been utilized 102, 103. More recently hypertonic saline (HTS) has proved 
useful in controlling ICP.  
HTS has been extensively studied in animal and human models of TBI 104-107. These 
experiments suggest that small volume resuscitation with HTS solution may be beneficial 
for increasing cerebral perfusion pressure and cerebral blood flow and decreasing ICP while 
maintaining hemodynamic stability following TBI. Animal studies comparing HTS and 
mannitol suggest that HTS is more effective in reducing ICP and has a longer duration of 
action 108, 109.  
In humans, HTS appears effective for reducing ICP in cases of refractory intracranial 
hypertension following TBI. Several studies have confirmed a significant decrease in ICP 
correlated with an increasing serum osmolality 110-112.  
In the past, researchers have combined hypertonic sodium with a variety of anions including 
acetate and lactate 113, 114. Acetate, a source of hydrogen ion acceptors, is an alternate 
source of bicarbonate by metabolic conversion in the liver. However, acetate is a myocardial 
depressant and can lead to hypotension in susceptible individuals. Hypertonic 
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sodium/lactate solutions have also been investigated. Whilst HTS/lactate is generally 
considered safe and may provide cerebral nutrition, there is some limited animal data 
suggesting that fluids containing lactate may be associated with significant toxic effects 115.  
Further research is required to clarify these issues. There is therefore a need for a solution 
able to address two fundamental problems related to TBI namely, refractory intracerebral 
hypertension and low cerebral energy levels. This could theoretically be accomplished by 
incorporating ketones into a hypertonic solution such as hypertonic saline.  
Firstly, the impact of the constituents on individual metabolism needs to be evaluated. The 
hypertonicity induced by 3% NaCl is well documented and desirable. However, the target 
Na is not known and various authors have reported concentrations as high as 185 mmol/l. 
Secondly, although the long term metabolic effects of ketone administration are described, 
little exists on the acute changes induced by intravenous infusions. For example, the entry 
of ketones into CSF is partly concentration dependent and therefore a certain serum 
concentration (possibly above 4 mmol/l) may be required for maximum utilization. What then 
is the effect of high ketone concentration on blood pH? It would be expected that such a 
solution would be alkalinizing, but this will be altered by the rate of metabolism. Thirdly, 
which ketone should be incorporate, acetoacetate or BHB? Both have been administered to 
humans in the past without ill effects. Fourthly, should CSF or plasma concentrations be 
utilized to guide therapy? And lastly, ketones are expensive to produce, therefore, can a 
commercially viable solution be developed? 
1.6.    Conclusion 
There is good theoretical evidence that administering ketones to patients with cerebral injury 
may provide a clinical benefit. While the use hypertonic saline has been demonstrated to 
improve intracranial hypertension in a number of clinical studies, the addition of ketones to 
the solution has the potential to improve cerebral metabolism. There are however, a number 
of outstanding questions requiring further consideration. These include dosing, timing, the 
route and duration of administration. Further research is necessary to clarify these issues 
and determine whether an HTS-ketone solution could be employed in the management of 
acute brain injury.  
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Chapter 2:  Prospective Evaluation of a Hypertonic Balanced Ketone 
Solution for use in Neuroprotective Strategies 
2.1    Synopsis and Citation 
Background:  
There is a need for a solution capable of addressing two fundamental problems related to 
TBI namely, intracranial hypertension and impaired cerebral energy production. While 
hypertonic saline has been utilized for a number of years to control intracranial hypertension, 
little attention has been paid to the provision of metabolic substrates capable of improving 
cerebral energetics. This could theoretically be accomplished by incorporating ketones into 
a hypertonic solution such as hypertonic saline. There are however, a number of challenges 
associated with the development of new parenteral solutions. 
Firstly, the impact of the constituents on individual metabolism needs to be evaluated. The 
hypertonicity induced by 3% NaCl is well documented and desirable. However, the target 
Na is not known and various authors have reported plasma concentrations as high as 185 
mmol/l (normal plasma Na range is 135 – 145 mmol/l). Secondly, although the long term 
metabolic effects of ketone administration are described, little published data exist on the 
acute changes induced by intravenous ketone infusions. For example, the entry of ketones 
into CSF is partly concentration dependent and therefore a certain serum concentration 
(possibly above 4 mmol/l) may be required for maximum utilization. Thirdly, the impact of an 
intravenous ketone solution on blood pH has not been fully evaluated. It would be expected 
that such a solution would be alkalinizing but this will be altered by the rate of metabolism. 
Fourthly, which ketone should be incorporate, acetoacetate or BHB? Both have been 
administered to humans without ill effects. Fifthly, should CSF or plasma concentrations be 
utilized to guide therapy? And finally, what are the effects on clinically measurable outcomes 
in humans?  
Aim:  
This was a proof of principle study to develop and investigate the effects of a hypertonic, 
ketone solution which can be used in the management of traumatic brain injury to 
treat/prevent intracranial hypertension and improve cerebral cellular energetics.  
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Design:  
Adult Sprague-Dawley rats (420-570g) were divided into 3 groups of 5, one control and 2 
study arms. The control group received an intravenous infusion of 3% NaCl at 5 ml/kg/h. 
The animals in the two study arms were assigned to receive one of the two formulations of 
ketone solutions, containing hypertonic saline with 40 mmol/l and 120 mmol/l beta-
hydroxybutyrate respectively. This was infused for 6 hours and then animal was euthanized 
and brains removed and frozen.  
Key Findings:  
Both blood and CSF concentrations of BHB demonstrated strong evidence of a change over 
time (p<0.0001). There was also strong evidence of a difference between groups 
(p<0.0001). Multiple comparisons showed all these means were statistically different 
(p<0.05). Measurement of BHB concentrations in brain tissue found strong evidence of a 
difference between groups (p<0.0001) with control: 0.15 mmol /l (0.01), BHB 40: 0.19 mmol 
/l (0.01), and BHB 120: 0.28 mmol /l (0.01). Multiple comparisons showed all these means 
were statistically different (p<0.05). There was no difference over time (p=0.31) or between 
groups (p=0.33) or an interaction between groups and time (p=0.47) for base excess.  
Conclusion:  
IV infusions of hypertonic saline/BHB are feasible and lead to increased plasma, CSF and 
brain concentration of BHB without significant acid/base effects.  
Citation:  
The information in this chapter has been adapted and combined from published and 
previously presented sources that include a previously published paper as an original 
manuscript. Figures and tables have been inserted into the text at slightly different positions 
and the numbering of pages, figures and tables has been adjusted to fit the overall style of 
the thesis. The references have been incorporated with the other references of the Thesis. 
The manuscript “Effect of a hypertonic balanced ketone solution on plasma, CSF and brain 
beta-hydroxybutyrate levels and acid-base status.” by White H, Venkatesh B, Jones M, 
Worrall S, Chuah T, Ordonez J was published in Intensive Care Medicine. 2013 
Apr;39(4):727-33 and extracts are reproduced with kind permission from Springer-Verlag 
copyright 2013 
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An oral presentation titled “A novel solution for the management of brain injury. Preliminary 
animal study” by White H, Venkatesh B, Jones M, Worrall S, Chuah T, Ordonez J, was 
presented at the College of Intensive Care Medicine National Annual Scientific Meeting, 
Melbourne 2012. 
Contributions:  
This prospective study was performed at the Biological Research Facility of the University 
of Queensland. I commenced work in July 2009 and was involved in the initial concept, all 
aspects of study design, data collection, data analysis and manuscript preparation. This 
work was carried out with the assistance of Dr Teong Chuah (assistance with study design 
and management), Ms Jenny Ordonez (intravenous fluid production), Dr Simon Worrall 
(analysis brain specimens and data analysis, manuscript preparation), Dr Mark Jones 
(statistical analysis) and Professor Bala Venkatesh (study design, data analysis and 
manuscript preparation). 
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2.2     Introduction 
Glucose is the major fuel for the brain in normally fed humans. However, during periods of 
fasting, ketones provide a significant contribution to cerebral energetics, up to 70% in 
prolonged starvation 27. Furthermore, during times of severe stress or cerebral injury, 
ketones become a significant source of energy. There is evidence to suggest preferential 
uptake of ketones over glucose by the injured brain 116. Several studies in animals have 
confirmed the benefit of exogenous ketone supplementation in terms of improvement in 
contusion size, cerebral blood flow and concentrations of adenosine tri-phosphate in 
traumatic brain injury and stroke models 53, 58, 73, 117.  
As the blood brain barrier (BBB) is relatively impermeable to ketones, cerebral uptake is 
via monocarboxylate transporter (MCT) proteins and increases with prolonged fasting 40, 41. 
Cerebral concentrations are therefore largely determined by plasma ketone concentration. 
Most studies of supplementation have examined a single bolus or a short term infusion of 
enteric or intravenous ketones on cerebrospinal fluid (CSF) and brain metabolism 42, 43, 75, 
118.   
Previous attempts to use ketones have been complicated by problems of hyperosmolarity 
and acid-base disturbances 42, 118.  Acetoacetate and -hydroxybutyrate (BHB) are strong 
anions and sodium salts of these when administered as a hypertonic IV infusion will tend to 
lower the strong ion difference of the plasma and may results in an initial metabolic acidosis, 
particularly if the rate of reduction of strong ion difference overwhelms the metabolic capacity 
of the liver to metabolise these anions. With time, metabolic clearance of these anions will 
result in an increase in plasma strong ion difference resulting in a metabolic alkalosis. For 
ketone supplementation to be a potentially therapeutic agent in patients with traumatic brain 
injury (TBI), a few challenges remain: achieving a formulation which can be administered as 
a prolonged infusion, which rapidly increases ketone concentrations in the brain, achieves 
a target hyperosmolarity and maintains neutral acid-base status. 
Hypertonic Saline (HTS) has been extensively studied in animal and human models of TBI 
and may be beneficial for increasing cerebral perfusion pressure and cerebral blood flow 
and decreasing intracranial pressure while maintaining hemodynamic stability 105, 107, 110. A 
solution containing both hypertonic saline and ketones would theoretically provide a number 
of advantages over current solutions including the ability to reduce intracranial pressures 
while providing a substrate capable of improving cerebral energetics. As no published data 
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exist on the effect of prolonged infusions of hypertonic NaBHB, the purpose of this study 
was to investigate hypertonic sodium ketone solutions with the aim of assessing the 
metabolic effects in general and specifically, on the brain. The aim of this study was to 
produce an intravenous hypertonic NaBHB (sodium D-3-hydroxybutyrate) formulation, to 
compare the impact of varying concentrations of BHB on plasma, CSF and cerebral BHB 
concentrations and examine their effect on plasma sodium and acid-base status.  
2.3      Materials and Methods 
This study was approved by the Animal Ethics Committee of the University of Queensland 
(PAH/029/09/UQ). Adult Sprague-Dawley rats weighing between 420 and 570g were utilized 
in the study. All animals were housed at the Biological Research Facility of the University of 
Queensland and were maintained according to the Standard Operating Procedures for the 
humane care of animals by the facility. Animals were provided with free access to food and 
water up to the time of the experiment.  
BHB solution 
The animals were divided into 3 groups of 5, one control and 2 study arms (see Table 2.1).  
Table 2.1    Baseline data (mean +/- SD) 
 Control (n=5) BHB 40 (n=5) BHB 120 (n=5) 
Weight (g) 498 ± 49 570 ± 64 420 ± 60 
HR (bpm) 266 ± 42 272 ± 11 274 ± 41 
SPO2 (%) 95 ± 2 98 ± 1 96 ± 1 
BHB, beta-hydroxybutyrate; BHB 40, 3% NaCl with 40 mmol/l; BHB 120, 3% NaCl with 120 mmol/l 
The control group received an intravenous infusion of 3% NaCl at 5 ml/kg/h. The animals in 
the two study arms were assigned to receive one of the two formulations of ketone solutions.  
The composition of the solutions is listed in Table 2.2. 
The rats in the control arm received 3% NaCl only while the two intervention groups received 
a 3% NaCl solution containing 40 mmol/l and 120 mmol/l of BHB respectively at 5 ml/kg/h. 
The D-3-hydroxybutyrate acid was manufactured by Sigma-Aldrich Pty. Ltd. (Castle Hill, 
NSW, Australia). The infusions were maintained for 6 hours. Bloods and CSF were sampled 
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at baseline, 1 hour and 6 hours.  At the end of the 6 hour period, the animals were 
euthanized. 
Table 2.2    Formulations of intravenous solutions 
 Na (mmol/l) Cl (mmol/l) BHB (mmol/l) 
Control 514 514 0 
BHB 40 514 474 40 
BHB 120 514 394 120 
BHB,  -hydroxybutyrate; BHB 40, 3% NaCl with 40 mmol/l; BHB 120, 3% NaCl with 120 mmol/l 
Preparation of solutions 
The solutions were prepared by the Therapeutic Research Center, University of 
Queensland. The solutions were prepared as follows. For the 40 mmol/l solution, 5.0436g/L 
of D-3-hydroxybutyrate Acid Sodium Salt was combined with 27.70 g/l NaCl to create a 3% 
solution (514 mmol/l) (see Table 2.1). 
Similarly, for the 120 mmol/l solution, the relative concentrations were 15.13 g/l D-3-
hydroxybutyrate Acid Sodium Salt and 23.03 g/l NaCl respectively. The appropriate amounts 
were weighted for the particular volume required.  The solution was mixed thoroughly until 
dissolved and prepared the same day of the experiments. 
Anaesthesia and vascular access 
The animals were anaesthetized using a facemask and 4% isoflurane in 100% oxygen. The 
isoflurane was subsequently decreased to 0.5 – 1.5% for maintenance. Intraperitoneal 
xylazine 3 mg/kg was also administered. Body temperature was maintained with an animal 
heating blanket. A 24 gauge BD Insyte IV catheter (Franklin Lakes, NJ USA) was inserted 
into a tail vein for continuous drug administration. A midline incision was made in the neck 
and a single common carotid artery was exposed and separated from surrounding tissues. 
A 24 GA BD Insyte catheter was inserted into the artery to monitor blood pressure and to 
collect blood samples. In order to maintain adequate oxygenation and control ventilation, a 
tracheostomy was performed. The trachea was dissected out and a small incision made 
between the rings. A 14 gauge BD Insyte IV catheter was shortened and inserted into the 
trachea and secured. The animals were attached to a Harvard Small Animal Ventilator 
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(Holliston, Massachusetts USA) using tidal volumes of between 1.5 and 2.0 ml per breath 
and rates from 80 – 120 bpm.  Heart rate and oxygen saturations were monitored with the 
Nellcor N-65 pulse oximeter (Covidien, Boulder, CO USA) 
Specimen collection 
Arterial blood specimens were taken at baseline, 1 hour and prior to euthanasia.  Tests 
included arterial blood gas with acid/base status (pH, base excess (BE) and HCO3), 
oxygenation, serum sodium and chloride and BHB concentrations. CSF specimens were 
obtained by performing a puncture into the cisterna magna using a 27 GA VanishPoint 
insulin syringe (Little Elm, Texas USA) and aspirating approximately 20 ul of CSF. BHB 
concentrations in the CSF specimens were measured. At completion of the study, the 
animals were euthanized using pentobarbital sodium at a dose of 15 mg/kg. Following 
euthanasia, the animals were decapitated and the brains were removed immediately, and 
stored at – 80 degrees Celsius for later analysis.  
Assays 
Plasma BHB 
Plasma BHB was measured quantitatively using the Stanbio Laboratory β-Hydroxybutyrate 
LiquiColor Assay Kit (Boerne, TX, USA) on the Beckman DxC800 Unicell (Brea, CA, USA) 
analyser using a spectrophotometric endpoint assay. The linearity of the assay is 0.0-4.0 
mmol/l with the coefficient of variation (CV) 3.0% at 0.38 mmol/l and CV 2.1% at 1.38 mmol/l.  
Brain BHB  
Brain tissue was homogenised into ice-cold saline and the clarified extracts were 
appropriately diluted for use in the BHB assay kit. Brain BHB concentrations were measured 
using the Cayman Chemical - β-Hydroxybutyrate (Ketone Body) Assay Kit (Ann Arbor, 
Michigan, USA). Briefly, the method for BHB determination is based upon the oxidation of 
D-3-Hydroxybutyrate to acetoacetate by the enzyme 3-hydroxybutyrate dehydrogenase. 
Concomitant with this oxidation, the cofactor NAD+ is reduced to NADH. In the presence of 
diaphorase, NADH reacts with the colorimetric detector WST-1 to produce a formazan dye 
with an absorbance maximum at 445-455 nm. The absorbance of the dye is directly 
proportional to the BHB concentration.  The range for the assay is 0-0.5 mmol/l.  All samples 
were diluted to fall within this range. 
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Acid-Base status and sodium 
Arterial blood gases and electrolytes were measured using the EC8+ cartridge with the 
Abbott Point of Care system, iSTAT (Abbott Park, Il, USA) (CV < 2.5%). The device was 
calibrated prior to use as per manufactures instructions.  
2.4    Statistical analysis 
Analysis of variance was used for analysis of BHB for blood, CSF and brain, as well as base 
excess (BE) and sodium (Na). Factors assessed were group (control, BHB 40, and BHB 
120), time (baseline, 1 hour, and 6 hour) as well as their interaction for all variables except 
brain which was only measured at study completion, hence only the group factor was 
included. A statistically significant interaction implies that changes over time differed 
between groups. Tukey’s method was used for multiple comparisons of significant (p<0.05) 
factors. Spearman’s correlation was used to assess the correlation between BHB for blood 
and CSF at the three time-points as well as brain at the final time-point. SAS version 9.1 for 
Windows and Stata Version 10.1 for Windows were used for the analysis. 
2.5   Results 
Plasma BHB 
Blood concentrations of BHB demonstrated strong evidence of a change over time 
(p<0.0001) with least squares means (standard error) at baseline: 0.19 mmol/l (0.03), 1 hour: 
0.29 mmol /l (0.03) and 6 hours: 0.47 mmol /l (0.03) (Figure 2.1).  
Multiple comparisons showed all these means were statistically different (p<0.05). There 
was also strong evidence of a difference between groups (p<0.0001) where the group least 
squares means (standard errors) were control: 0.21 mmol /l (0.03), BHB 40: 0.26 mmol /l 
(0.03), and BHB 120: 0.48 mmol /l (0.03). BHB 120 mean was statistically larger than that 
for BHB 40 (p<0.05) and control (p<0.05) but there was no evidence of a difference between 
control and BHB 40. There was no evidence of an interaction between group and time 
(p=0.071) (Table 2.3).  
CSF BHB 
BHB concentrations in CSF demonstrated strong evidence of a change over time (p<0.0001) 
with least squares means (standard error) at baseline: 0.15 mmol /l (0.02), 1 hour: 0.23 
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mmol /l (0.02) and 6 hours: 0.36 mmol /l (0.02). Multiple comparisons showed all these 
means were statistically different (p<0.05). 
Table 2.3   BHB data for 3 time points (mean +/- SD) 
 BHB blood (mmol/l) BHB CSF (mmol/l) Brain BHB 
(mmol/l) 
Control (n=5)    
Baseline 0.16 ± 0.05 0.22 ± 0.04  
1 hour 0.18 ± 0.08 0.18 ± 0.08  
6 hours c 0.28 ± 0.08 0.28 ± 0.11 0.15 ± 0.02 
BHB 40ab (n=5)    
Baseline 0.14 ± 0.01 0.14 ± 0.01  
1 hour 0.22 ± 0.04 0.26 ± 0.05  
6 hours cd 0.43 ± 0.05 0.38 ± 0.05 0.19 ± 0.01 
BHB 120ab (n=5)    
Baseline 0.26 ± 0.05 0.10 ± 0  
1 hour 0.48 ± 0.13 0.24 ± 0.09  
6 hours c 0.70 ± 0.27 0.43 ± 0.11 0.28 ± 0.02 
BHB, beta-hydroxybutyrate; BHB 40, 3% NaCl with 40 mmol/l; BHB 120, 3% NaCl with 120 mmol/l 
a = In both groups, change over time was significant: values at 6 hrs significantly > 1 hr significantly> baseline 
for both plasma and CSF 
b = There was a significant difference in plasma BHB concentrations between BHB 120 and BHB 40 at 1hr and 
6 hrs. 
c = For brain BHB concentrations there was a strong evidence of a difference between groups (p<0.0001) 
d n = 4 for this group. A single specimen returned a blood BHB concentration of 3.8 mmol/l and CSF BHB 
concentration of 1.8 mmol/l at 6 hours. As the outlier had values that were 28 standard deviations greater than 
the mean for CSF BHB (based on the other 4 rats in the group) and 67 standard deviations greater than the 
mean for blood BHB (based on the other 4 rats in the group), the results were removed from the analysis 
There was no difference between groups (p=0.46) however there was evidence of an 
interaction between group and time (p=0.009) where there was an increase in BHB CSF 
over time in the BHB 40 and 120 groups but not the control group. To investigate the change 
in BHB CSF over time separate analyses were conducted on the 3 groups. Results showed 
evidence of change over time for BHB 40 group (p=0.001) and for the BHB 120 group 
(p=0.0005) but not for the control group (p=0.21) (Figure 2.2). 
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Brain BHB 
For BHB concentrations there was strong evidence of a difference between groups 
(p<0.0001) where the group least squares means (standard errors) were control: 0.15 mmol 
/l (0.01), BHB 40: 0.19 mmol /l (0.01), and BHB 120: 0.28 mmol /l (0.01). Multiple 
comparisons showed all these means were statistically different (p<0.05). 
There were no differences over time (p=0.31) or between groups (p=0.33) or an interaction 
between groups and time (p=0.47) for base excess (see Table 2.4). An analysis of just the 
final time-point also showed no difference between groups for base excess (p=0.24). For 
Na there was evidence of a difference over time (p<0.0001) but not between groups (p=0.24) 
or interaction between groups and time (p=0.15). Least squares means (standard error) 
were, at baseline: 137 mmol /l (1.5), 1 hour: 143 mmol/l (1.5) and 6 hours: 154 mmol/l (1.5). 
Multiple comparisons showed all these means were statistically different (p<0.05). 
Table 2.4   Acid base and electrolyte data for 3 time points (mean +/- SD) 
 pHa BEa (mmol/l) Serum Nab 
(mmol/l) 
HCO3a (mmol/l) 
Control (n=5)     
Baseline 7.49 ± 0.17 2.8 ± 3.7 137 ± 7 24.6 ± 2.3 
1 hour 7.55 ± 0.07 0 ± 2.6 145 ± 2 20.6 ± 3.3 
6 hours 7.50 ± 0.10 - 1.2 ± 3.7 153 ± 7 21.0 ± 4.1 
BHB 40 (n=5)     
Baseline 7.35 ± 0.09 3.0 ± 4.3 137 ± 4 28.8 ± 4.6 
1 hour 7.32 ± 0.10 1.6 ± 3.4 142 ± 6 27.6 ± 3.2 
6 hours 7.34 ± 0.08 1.0 ± 2.9 150 ± 4 26.4 ± 3.0 
BHB 120 (n=5)     
Baseline 7.37 ± 0.19 1.4 ± 3.5 138 ± 5 26.4 ± 2.6 
1 hour 7.41 ± 0.42 3.2 ± 1.6 141 ± 5 27.8 ± 1.4 
6 hours 7.38 ± 0.05 2.0 ± 1.9 160 ± 9 26.8 ± 1.6 
BHB, beta-hydroxybutyrate; BHB 40, 3% NaCl with 40 mmol/l; BHB 120, 3% NaCl with 120 mmol/l 
a There was no statistically significant difference over time or between groups 
b Multiple comparisons showed all for all groups, the means were statistically different from baseline to 6 hours 
(p<0.05). 
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In a final analysis there was evidence of correlation between BHB blood and CSF at 6 hours 
(correlation = 0.81, p<0.0001) but not at baseline (correlation = 0.0, p=0.99) or 1 hour 
(correlation = 0.31, p=0.26). There was evidence of a correlation between BHB blood and 
brain at 6 hours (correlation = 0.67, p=0.012) as well as between BHB CSF and brain at 6 
hours (correlation = 0.62, p=0.023). In both groups, change over time was significant: values 
at 6 hrs significantly > 1 hr significantly > baseline for both plasma and CSF. There was a 
significant difference in plasma BHB concentrations between BHB 120 and BHB 40 at 1hr 
and 6 hrs. 
 
Figure 2.1   Plasma beta-hydroxybutyrate profiles 
BHB, beta-hydroxybutyrate; BHB 40, 3% NaCl with 40 mmol/l; BHB 120, 3% NaCl with 120 mmol/l 
2.6    Discussion 
We were able to demonstrate that a continuous infusion of BHB in non-fasted rats led to 
steadily increasing plasma and CSF concentrations of BHB. Furthermore, BHB 
concentrations in both plasma and CSF increased as the BHB concentration in the 
intravenous formulations increase. Despite this, there were no significant effects on acid-
base metabolism at concentrations used. Furthermore, the solution achieved a desirable 
level of hypernatremia necessary for managing intracranial hypertension. 
Prior studies have only examined the effects of short term BHB infusions on BHB 
concentrations. Suzuki et al used infusions of BHB to examine effects in acute brain injury 
but blood concentrations were not reported 73. Katayam et al administered an isotonic 
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solution of BHB at 30 umol/kg/min for 2 hours in a hemorrhagic model 119. This led to BHB 
concentrations of approximately 1.5 mmol/l. However, the treatment animals demonstrated 
a significant alkalosis with final pH 7.54. Prins et al while examining the cerebral uptake of 
BHB in rat model of TBI administered 30 mg/kg/h for 3 hours 75. 
 
Figure 2.2   Plasma and CSF BHB concentrations with different fluids at various time points. 
BHB, beta-hydroxybutyrate; BHB 40, 3% NaCl with 40 mmol/l; BHB 120, 3% NaCl with 120 mmol/l 
Comparison with previously published data 
There was an increase in BHB concentrations, to a peak of 0.41 mmol/l with no alteration in 
pH. As part of a study examining effects of BHB on cerebral blood flow and cerebral oxygen 
delivery, Linde et al examined the effect of administering 37.5mg/kg/min of BHB to rats over 
a period of 2 hours 118. They demonstrated a rapid increase in pH to 7.52 which loosely 
correlated with the increase in serum BHB concentrations to 6.08 mmol/l. 
Some authors have suggested that high plasma concentrations of BHB are necessary to 
produce a beneficial effect on cerebral energetics. As such many studies have administered 
large concentrations of BHB over short periods of time to rapidly increase blood BHB 42. 
This is not necessarily true as relatively small increases in BHB may be sufficient to improve 
cerebral metabolism. Although a correlation exists between blood BHB concentration and 
cerebral uptake there is period of adaptation as the MCT transfer molecules are upregulated 
over time 120, 121 Therefore, cerebral uptake of BHB is not only dependent on plasma 
concentration but also increases following prolonged hyperketonemia 42, 43. This was 
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demonstrated by Linde et al following an acute increase in peripheral BHB concentrations 
to greater than 6 mmol/l 118. They observed no decrease in glucose metabolism and no 
substitution of glucose by ketone bodies for oxidate metabolism, suggesting adaptation had 
not yet occurred. Pan et al demonstrated a small, but statistically significant increase in 
cerebral ketones (0.24 ± 0.04 mmol/l) following a 75 min infusion of BHB but this was 
considerably lower in comparison with previous data acquired from fasted adults 43. These 
findings suggest the way the brain handles BHB is different following acute as compared to 
chronic hyperketonemia and likely represents transport upregulation.  
We demonstrated that ketones could be readily measured in CSF and that there was a 
progressive increase in CSF concentration. We also found an increase in CSF 
concentrations related to concentration of solution administered. This is despite the fact that 
the rats were not starved before the study. Furthermore, the effect was likely related to BHB 
infusion as CSF concentrations did not change significantly in the control group. Similarly, 
there was a significant increase in brain tissue BHB concentrations which depended on the 
amount of BHB administered. Pan et al using H+ magnetic resonance spectroscopy were 
able to show an increase in occipital lobe concentrations of BHB in healthy human subjects 
following a 75 min infusion of BHB 43. Although Pan reached blood concentrations of 2.12 
mmol/l the cerebral BHB concentration was only 0.24 mmol/l whereas we achieved a 
significant increase by administering a lower concentration of BHB over a prolonged period. 
Furthermore, there was no comment on the effects of these concentrations on pH. Pan 
previously demonstrated the effects of prolonged ketone exposure on cerebral 
concentrations with significant increases in cerebral ketones after 48 and 72 hours starvation 
42.  
Several prior studies have demonstrated the development of a significant metabolic 
alkalosis following BHB infusion 95. Blood pH reached a maximum of 7.6 following BHB 
infusion during the study by Linde et al. Concentration, rate of administration and length of 
administration are likely to be important factors in determining acid/base response. 
Metabolic alkalosis has several potential deleterious effects on cerebral metabolism 122-124. 
These include a decrease in CBF, lethargy and confusion and if severe, coma and seizures. 
More specifically, Gillard et al found an alkaline pH exacerbated glutamate induce 
excitotoxic neuronal damage and appeared to sensitize neurones to ischemic injury and 
potentiate reperfusion injury 125.  Alkalosis has been shown to decrease CBF in a number of 
animal studies by both Arvidsson et al and Pannier et al 122, 124. Furthermore, Schrock et al 
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demonstrated a decrease in CBF and glucose utilization during severe hypochloremic 
alkalosis 123. This is in contrast to the ketogenic diet which generates protons and pH-
lowering metabolic products. The decreased pH was initially considered to be a key seizure 
preventing aspect of the KD. However, there is little evidence that ketone administration 
decreases cerebral pH other than briefly and less that this is associated with anticonvulsant 
activity.  
Bourdeaux et al on the other hand, found infusions of 8.4% sodium bicarbonate effective at 
reducing intracranial pressure although whether the hypertonic nature of the solution or 
alkalinizing effects were responsible is not clear 126. We found that concentrations of BHB 
up to 120 mmol/l were well tolerated with no significant change in base excess over time. 
Others have observed BHB containing solutions to be alkalinizing at high doses when 
administered over short periods 118. This is likely due to the insufficient time for acid/base 
homeostasis to occur. The clinical effects of this have not been investigated.  
As one of the potential uses of this solution includes the management of intracranial 
hypertension in patients with traumatic brain injury, a key outcome was to demonstrate the 
solution to be capable of producing hyperosmolar conditions. All solutions were able to 
achieve this and the concentration of BHB did not alter the outcome. Hyperosmotic therapy 
has been the corner stone of the management of intracranial hypertension for a number of 
years. In many units, hypertonic saline has replaced mannitol as the principle solution 127. 
HTS has a number of potential benefits including a high coefficient of reflection, 
maintenance of BBB integrity, modulation of inflammatory response and augmentation of 
volume resuscitation. Furthermore, a number of animal and human studies have confirmed 
it as an effective treatment for intracranial hypertension 128, 129. A combined solution of 
hypertonic saline and BHB could provide the benefits of hyperosmolar therapy with improved 
cerebral energetics 130.   
Limitations 
There are several limitations of our study. Although the infusion lasted 6 hours, longer than 
most prior studies, this is still relatively short. The effects of longer duration infusions are 
unknown although a number of studies have examined prolonged hyperketonemia induced 
by either diet or starvation. Secondly, we did not measure clinical endpoints such as 
intracranial pressure, cerebral perfusion pressure or CBF. Nor did we look at cerebral 
metabolic neuroprotective endpoints such as reductions in reactive oxygen species and 
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mitochondrial permeability transition complex although prior studies have demonstrated 
improved brain energetics from ketones as compared to glucose. And thirdly, we used 
healthy rats. The pharmacokinetic and pharmacodynamic effects cannot necessarily be 
extrapolated to head injury models as the blood brain barrier permeability and cerebral 
metabolism cannot be predicted. Experiments in acute brain injury models demonstrate an 
increase in uptake and utilization of ketones leading to decrease contusion size.  
2.7    Conclusion 
We have demonstrated that IV infusions of hypertonic saline/BHB are possible and lead to 
increased plasma and CSF BHB concentrations in healthy rats and that increases in brain 
concentrations of BHB are dependent on plasma concentrations. Solutions containing 40 
and 120 mmol/l of hypertonic NaBHB do not lead to metabolic acidosis and are capable of 
producing adequate hypernatremia.  
Following on from the animal work, the next stage of the project is the development of an 
intravenous hypertonic solution containing BHB that can be administered to humans. A 
number of challenges exist including determining the optimal concentration of ketones 
necessary to impact on cerebral energetics and the overall impact on outcome. The pitfalls 
of such a project are examined in the next chapter. 
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Chapter 3:  Proposed Project: Hypertonic Ketone Infusion for the 
Management of Acute Brain Injury 
3.1    Synopsis and Citation  
Aims:  
The aim of this chapter was to examine the challenges involved in producing an intravenous 
hypertonic ketone solution and potential alternatives to the parenteral route for increasing 
the plasma ketone concentration.  
Citation:  
This chapter has been adapted from: 
An oral presentation titled “Ketone infusion for the management of acute brain injury” by H 
White and B Venkatesh. This was presented at the ANZICS CTG Winter meeting Melbourne 
2012. (Oral presentation by H White). 
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3.2     Development of a hypertonic ketone solution for humans with brain injury   
Following the results from the animal study (see chapter 2), the next stage of the project 
was to develop and assess the effects of a hypertonic saline/BHB (HTS-BHB) solution in 
human subjects with brain injury. Intravenous ketone solutions have been evaluated in 
humans before 95. Outcomes differ but mainly relate to effects on cerebral concentrations of 
BHB and varying metabolic endpoints. Of note is that there are no reports of serious adverse 
events from administration of intravenous ketone containing solutions in humans. Below is 
a summary of human studies of intravenous ketones; 
Studies of intravenous ketones in humans 
Owen et al (1973) investigated the influence of ketone bodies on insulin and FFA release in 
response to rapid IV infusion of sodium acetoacetate (NaAcAc) 96. The ketones solution was 
made from ethyl acetoacetate. It was administered as a rapid solution of NaAcAc at 1.0 
mmol/kg after overnight fast in 12 adults weighing between 88 – 215% of ideal body wt. 
Ketone concentrations peaked 30 min after infusion at 4.74 mmol/l and then rapidly declined 
(similar to long term starvation). Glucose concentrations remained stable. The main finding 
from this study was that the utilization of ketone bodies increased with rising blood 
concentrations, with a plateau at approximately 128g/24 hours. Also, when total ketone body 
concentrations were below 2.0 mmol/l, there was a linear relationship between ketone body 
utilization rates and concentration.  
Miles et al (1983) investigated the potential protein sparing effects of ketone bodies using 
an intravenous infusion of sodium beta-hydroxybutyrate (NaBHB), prepared as a 3M 
solution 131. Six healthy volunteers received the infusion at a rate of 15-30 umol/kg/min for 
3 hours. Blood ketone concentrations increased to 2.33 mmol/l while lactate peaked at 0.95 
mmol/l. pH increased from 7.43 to 7.52. Contrary to the belief of many, the infusion of a 
ketone salt is likely to have an alkalinizing effect. Glucose remained stable at 4.7 mmol/l. No 
adverse effects were reported and the infusion did not appear to decrease proteolysis.  
Hiraide et al (1991) looked again to further assess the potential protein sparing effects of a 
ketone infusion in 20 trauma patients 94. Eleven patients received a 3 hour infusion of BHB 
at 25 umol/kg/min while 9 control patients received a sodium lactate infusion at a similar 
rate. Total ketone concentrations in the intervention group reached a peak of 1.5 ± 0.42 
mmol/l. Glucose concentrations remained unchanged but a decrease alanine release from 
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muscle was demonstrated suggesting that ketones have a suppressive effect on 
posttraumatic protein catabolism.  
CNS effects of intravenous ketone solution 
A number of investigators have investigated the ability of exogenous ketone solutions to 
enter the cerebral tissue. Pan et al (2001) measured BHB in the human brain of 6 normal 
adult volunteers following an infusion of Na-BHB 200 mmol/l solution 42, 43. The 6 patients 
fasted overnight and then received an infusion of BHB at a bolus rate of 80 um/kg/min 
followed by 20 um/kg/min for 75 min. BHB blood concentrations reached a steady state of 
2.12 ± 0.30 mmol/l. BHB concentrations in the occipital lobe of the brain were measured 
using MRI spectroscopy. BHB brain concentrations were measured at 0.24 ± 0.04 mmol. 
Although elevated, this proved to be lower than brain tissue concentrations measured after 
a 48 hour fast, suggesting that upregulation of MCT transporter is required before cerebral 
BHB concentrations can increase significantly. 
Similarly, Blomqvist et al (2002) investigated the factors influencing BHB utilization and 
uptake by the brain in 6 patients with diabetes and 6 non-diabetic volunteers 132. Using 
positron emission tomography, they studied the effect of acute hyperketonemia (range 0.7-
1.7 mmol/l) on cerebral ketone body utilization. The volunteers received an infusion of BHB 
for one hour followed by a bolus injection of radiolabelled BHB. Utilisation rates were found 
to correlate with plasma ketone concentrations in both groups, confirming that BHB 
utilization by cerebral tissue is dependent on transportation into the brain. 
Smith et al (2005) reported on a novel compound called KTX 0101 (which was undergoing 
development) 88. They reported that the compound was administered to 20 healthy 
volunteers, was well tolerated and with no serious adverse events. The company, 
KetoCytonyx was proposing to develop the solution for neuroprotection in cardiopulmonary 
bypass. However, no final publication was ever submitted and the product is not available 
commercially 
As can be seen from the above studies, a number of patients have received ketone 
administrations intravenously without major side effects. The key points are: 
1. Intravenous BHB appears well tolerated 
2. Problems with alkalemia are likely due to the high relative concentrations of BHB     
administered over a short period. While the concentration of BHB in the brain is 
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related to plasma concentrations, there is also a relationship with time as protein 
transporters are required to carry BHB across the blood brain barrier and this 
process takes time to up regulate.  
3. No outcome studies have been undertaken in patients with traumatic brain injury.  
4. There are no studies evaluating hypertonic saline BHB solutions exist. 
We therefore intended to undertake a study using a prolonged infusion of hypertonic 
saline/BHB which will examine a number of clinical endpoints. 
3.3    Proposed Project Plan  
Objectives:  To safely deliver a 72 hour continuous infusion of 3% HTS-BHB (80 mmol/l) 
and demonstrate hyperosmolality could be achieved.  
Secondary objectives:   
•    Demonstrate a significant increase in serum ketones as compared to control.  
• Demonstrate equivalent control of ICP and CPP compared to controls 
• Demonstrate stable acid-base status during infusion 
Study design 
The study was to take place at a tertiary ICU where neurological services manage patients 
with severe traumatic brain injury. Our aim was to recruit 40 patients with brain injury and 
intracranial pressure monitoring.  
Following admission to ICU, patients would have been randomized into 2 groups. The 
control would have received standard care including 3% hypertonic saline for management 
of intracranial hypertension. The intervention group would have received 3% hypertonic 
saline/BHB (80 mmol/l). The solution infusions would have begun at 40 mls per hour. The 
subsequent rate of infusion would have been titrated to maintain Na in the range of 145 – 
155 mmol/l. The infusions of HTS/BHB would have continued for 72 hours and then replaced 
with HTS at the discretion of the treating consultant. Observations were to continue for a 
further 24 hours. 
Formulation of solution: 
The NaBHB solution to be used for the infusion was to be formulated as follows; 
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10.08 g of sodium D-3-hydroxybutyrate will be combined with 24.78 g of NaCl in 1 L of water. 
Sterility and stability studies will be undertaken as part of the product development. 
Data Collection 
For all patients, data was to be collected at baseline and then 4 hourly for 96 hours. This 
included: 
• Vital signs including GCS and temperature 
• Intracranial pressure 
• Medication used for sedation and paralysis 
• Inotropes and pressor use 
• Calorie intake 
Laboratory data would have been collected a minimum of 12 hourly 
• ABG 
• Electrolytes 
• Beta-hydroxybutyrate and acetoacetate 
• Lactate and glucose 
• Patients with intraventricular drains – CSF BHB, glucose, lactate  
At the end of the study, a lipogram would have been performed to assess effects on lipid 
metabolism 
Study population 
Inclusion criteria; 
• 18 years of older 
• Severe traumatic brain injury requiring intracranial pressure monitoring 
• Life expectancy of at least 72 hours 
Exclusion criteria 
• Failure to obtain written consent from patient or substitute decision maker 
• Pregnancy 
• Non-survivable injury or brain death 
• Patients considered for organ donation 
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• Type I diabetes 
Data analysis 
Categorical data would have been compared using Fishers Exact test. Continuous data 
would have been compared using Wilcoxon 2-sample test. Repeated measures continuous 
data was to be analysed using linear mixed models. 
Outcomes and significance:  
Study outcomes 
Primary outcome 
• Achievement of a target sodium of 145 – 155 mmol/l 
• Beta-hydroxybutyrate and acetoacetate concentrations in blood 
Secondary outcome 
• Acid-base status including pH and Base Excess 
• ICP and CPP 
• Glucose and lactate concentrations 
As this study would be used to understand the power of a larger trial, we would be recording 
ICU/hospital length of stay and mortality although we do not expect to see significant 
differences in these outcomes. 
Adverse events 
There is minimal data on the adverse effects of ketone administration, much of which is 
based on chronic intake via the enteral, rather than the parenteral route. In the acute setting, 
effects of parenteral formulations on pH, Na, lipids and glucose are likely to dominate e.g. 
IV formulations would theoretically be alkalinising, depending on the ketone concentration. 
This was confirmed by Hiraide et al who noted a significant increase in pH and Na 
concentrations following the IV administration of a 20% solution of NaBHB to severe trauma 
patients94. Also of potential concern is the reduction in glucose cerebral metabolism and 
increase in CBF demonstrated by Hasselbalch et al during administration of intravenous 
BHB 58. The long term consequences of this are not known.  
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Some side effects are predictable following enteral administration such as dehydration and 
hypoglycemia. Others are less common and present following prolonged use, including 
growth retardation, obesity, nutrient deficiency, decreased bone density, hepatic failure, and 
immune dysfunction. Freeman has reported a significant rise in mean blood cholesterol to 
over 250 mg/dl following prolonged intake a of ketogenic diet 99. This in turn may be 
atherogenic, leading to lipid deposition in blood vessels. In addition, there are reports of 
dilated cardiomyopathy in patients on the ketogenic diet, possibly as a consequence of the 
toxic effects of elevated plasma free fatty acids. Finally, an increased incidence in 
nephrolithiasis in patients on the ketogenic diet as well as increases in serum uric acid 
secondary have been reported 76, 100. 
The fact that patients are critically ill and monitored continuously in an ICU should mitigate 
against any unrecognized side effects. Patients will also receive continuous nutrition as per 
standard ICU protocol. Glucose, pH and Na will be regularly measured.  
In this study, reporting of adverse events would have been restricted to events that are 
considered to be related to study treatment. Serious adverse drug reactions (SADRs) that 
were thought to be study treatment related would be reported immediately to the chief, or 
co-investigators. These would have then been reported to the HREC. The definitions of 
SADRs were as follows; 
• Results in death 
• Is life-threatening 
• Requires inpatient hospitalisation or prolongation of existing hospitalisation 
• Results in persistent of significant disability 
• Is a congenital anomaly 
3.4 Challenges to PhD in its current design and proposed changes to PhD title and 
project focus 
Following discussions with several compounding chemists including Stenlake (Sydney, 
NSW), it became apparent that while the production of an intravenous hypertonic saline 
solution containing BHB was feasible, it was also extremely costly. The main reason for this 
was not related to the production of the solution as such but rather high cost of sourcing the 
BHB compound. The estimates at the time were approximately 1000 AUD per one litre bag 
(personal correspondence). Given that patients would require several bags over the course 
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of their treatment, the costs for the proposed study were in the region of 100 000 AUD. 
Applications were made to both Queensland Emergency Medical Research Fund (QEMRF) 
and ANZICS Research Foundation for funding but was declined. A presentation was also 
made to the Australia and New Zealand Intensive Care Society Clinical Trials Group 
(ANZICS CTG) but did not receive favorable review. The reasons for rejecting the funding 
application included; concern about the lack of animal and human data required for a phase 
II study, the high cost of the product making the funding of further studies unlikely, the 
uncertainty related to the efficacy of the chosen concentration of BHB and concern regarding 
an appropriate outcome measure for the study.  
The mechanism by which ketosis is induced does not appear to impact on the clinical 
outcome. Therefore, the oral route was investigated as an alternative option. A major 
challenge is that inducing ketosis in adult humans with conventional ketogenic feeds is 
difficult. Furthermore, the concentrations of BHB attainable purely through feeding may not 
be adequate for ABI patients. A group in Oxford University led by Professor Kieran Clarke 
was investigating the production of a ketone ester which had the potential for rapidly 
increasing plasma ketone concentrations. It was clear however that the product was still in 
development and it would be a number of years before it became available.  
As such we were forced to look at the use of a commercially available ketogenic feed, 
KetoCal. This would require certain modifications as the feed was not designed for critically 
ill adults. This process is further discussed in Chapter 7. 
It was therefore necessary to alter the focus of this PHD to evaluating ketosis induced by 
enteral formulation. As such, the title of the PHD was altered from 
“Development of a novel solution for treating patients with acute brain injury” to  
“Evaluation of a ketogenic formulation for treating patients with acute brain injury” 
The following chapters will investigate the potential issues involved in providing ketogenic 
feeds enterally to critically ill patients with ABI, evidence supporting ketogenic feeds in this 
group of patients, alternatives to ketones for improving cerebral cellular energetics and the 
outcomes from providing a modified ketogenic feed to a cohort of patients with ABI.  
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Chapter 4:  Serial changes in plasma ketone concentrations in patients 
with acute brain injury  
4.1 Synopsis and Citation 
Background:  
Acute brain injury (ABI) is a catastrophic event, leading to disruption of the normal cerebral 
metabolic pathways and a subsequent cerebral energy deficit. Ketones (beta-
hydroxybutyrate and acetoacetate) may represent an alternative metabolic substrate with 
the potential to improve cerebral energy supply and decrease injury. 
Aim:  
The purpose of this study was to evaluate baseline ketone concentrations in the ABI 
population. 
Design:  
This was a prospective cohort observational study of 38 patients with ABI followed for up to 
7 days. We collected arterial blood samples immediately after admission and daily to 
measure the concentrations of beta-hydroxybutyrate and acetoacetate. Where possible, 
matching cerebrospinal fluid (CSF) specimens were also collected.  
Key Findings:   
During the study period, plasma BHB concentrations were increased initially but normalized 
by day 3 while acetoacetate concentrations remained within the normal range. The change 
in BHB was significant. There were 30 observations in 10 patients where BHB could be 
measured in both blood and CSF. When the data was averaged over patients there was a 
weak correlation between blood and CSF BHB (Spearman’s rho = 0.62, P=0.054). 
Conclusion:   
Blood ketone concentrations remain low within the ABI population. An external source of 
ketones will be required to increase blood concentrations to clinically relevant levels.  
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Citation:  
The material presented in this chapter has been previously published as an original 
manuscript. Figures and tables have been inserted into the text at slightly different positions 
and the numbering of pages, figures and tables has been adjusted to fit the overall style of 
the thesis. The references have been incorporated with the other references of the Thesis. 
The manuscript “Serial changes in plasma ketone concentrations in patients with acute brain 
injury.” by Hayden White, Balasubramanian Venkatesh, Mark Jones & Hesly Fuentes was 
published in Neurological Research 2017;39:1-6 and extracts are reproduced with kind 
permission from Taylor and Francis, copyright 2017. 
Contributions:  
This prospective observational study was performed at Logan Hospital (Meadowbrook) and 
Princess Alexandra Hospital (Brisbane), Australia. I commenced this work in May 2013 and 
was involved in the initial concept, all aspects of study design, data collection, data analysis 
and manuscript preparation. This work was carried out with assistance from Ms Lynette 
Morrison (data collection), Dr Mark Jones (statistical analysis), Ms Kellie Sosnowski (data 
collection), Professor Bala Venkatesh (study design and manuscript preparation), Dr Hesley 
Fuentes (data collection) and Mr Jason Meyer (recruitment and data collection). 
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4.2 Introduction 
Acute brain injury (ABI) including, traumatic brain injury (TBI), cerebrovascular accident 
(CVA) and subarachnoid haemorrhage (SAH) are common and catastrophic events 
resulting in significant morbidity and mortality. Much of the pathophysiology leading to the 
ongoing injury relates to disruption of the normal metabolic pathways of the brain and the 
subsequent inability to adequately meet cerebral energy requirements. While glucose under 
normal circumstances provides the major substrate for cerebral metabolism, hyperglycemia 
clearly leads to worse outcomes following ABI133. Ketones may represent an alternative 
source of fuel in these instances 1.  
Ketogenesis is the process by which ketone bodies (beta-hydroxybutyrate and 
acetoacetate), during times of starvation or catecholaminergic stress, are produced via fatty 
acid metabolism. In health, glucose is the brain’s main metabolic substrate for fulfilling 
energy requirements 4. During times of oxidative stress however, the brain may alter its 
ability to use glucose as a substrate for metabolic activity134. During these periods, ketones 
are capable of supplying up to 70% of basal cerebral energy requirements 51. There is 
evidence that after acute brain injury, ketone utilization may be preferred to glucose, that it 
improves cerebral energy production and decreases cerebral injury 135. Animal models 
simulating both rapidly developing pathologies (glutamate excitotoxicity, hypoxia/ischemia) 
and neurodegenerative conditions (Parkinson’s disease, Alzheimer’s disease) and more 
recently TBI have found ketosis produces a number of beneficial effects including; improved 
cerebral energetics, decrease cerebral injury and improved cerebral blood flow 73, 136. 
There is a paucity of research examining ketones in critically ill patients with ABI and the 
role of ketone supplementation. Existing research has demonstrated a number of potential 
benefits to exogenous ketone administration. These include; that ketones can be given 
enterally or intravenously with minimal side effects, utilization of ketone bodies increase with 
rising blood concentrations, hyperketosis is associated with improved glucose control, 
increased plasma concentrations lead to increase in cerebral uptake and improvement in 
cognitive function in patients with chronic neurodegenerative disorders. However, well 
designed outcome studies are lacking 43, 83, 91, 94.  
Many unanswered questions remain including optimum route of administration and target 
plasma concentration. Generally, plasma ketone concentrations can range from <0.1 mmol/l 
in the postprandial state to over 6 mmol/l during prolonged fasting/starvation states and may 
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reach 25 mmol/l in uncontrolled diabetes. However, little is known about ketone physiology 
during critical illness and ABI.  
Tamaki et al investigated the physiologic changes to ketone bodies in patients with SAH 137. 
They noted a strong correlation between ketone body concentrations and catecholamine 
levels. Although the pathogenesis differs, many regulatory hormones are abnormally raised 
post ischemic stroke, TBI or SAH. As such, catecholamine, cortisol and glucocorticoid levels 
are universally increased acutely while there is evidence that the production of counter 
regulatory hormones such as insulin may be impaired 138-140.  
The principle drivers for ketogenesis include fasting (glucopenia) and catecholaminergic 
stress1. We hypothesised that ketone concentrations would remain low in patients with ABI 
although, the impact of critical illness with its associated catecholaminergic stress is 
unpredictable. Furthermore, the unpredictability of enteral absorption during the critically ill 
period may lead to altered glucose and insulin metabolism. Prior to undertaking studies on 
ketone supplementation in these patients, it is important to quantify baseline concentrations. 
The purpose of this study is to examine the physiological changes in ketone concentrations 
following ABI. 
4.3 Materials and Methods 
This dual-site, prospective, observational study was conducted over a 12 month period to 
define baseline ketone concentrations in plasma and cerebrospinal fluid (CSF) following 
acute brain injury.  The study setting was two metropolitan Intensive Care Units (ICU). Ethics 
approval was granted by the Princess Alexandra Hospital Human Research Ethics 
Committee (HREC/13/QPAH/150). The requirement for written informed consent was 
waived by the institutional review board.  
Patients were enrolled as soon as possible following admission to ICU or following diagnosis 
of CVA. All patients > 18 years old with an ICP monitor admitted to ICU following TBI, SAH 
or acute CVA were included. (CVA patients did not require ICP monitor to be included). 
Exclusion criteria included type I diabetes and pregnancy. 
Patients’ fulfilling the inclusion criteria had blood samples collected immediately following 
enrolment and then daily from the morning specimens. All clinical observations were taken 
on admission and then from 8 am daily. Patients remained on study for 7 days or until death 
or discharge from ICU. Samples were obtained simultaneously for ketones (both Beta-
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hydroxybutyrate and acetoacetate), glucose and arterial blood gases: (pH, CO2, HCO3, base 
excess, anion gap, lactate). If an extraventricular device was present (SAH), CSF was tested 
for BHB and Acetoacetate. 
Acetoacetate concentrations were determined using an automated modification of the 
original endpoint procedure described by Williamson et al on a Cobas Bio centrifugal 
analyser17 (Roche, Basel, Switzerland). Specimens were collected in lithium heparin tubes 
(#456083, Greiner Bio-One, Kremsmunster, Austria). The linearity of the assay is 0.008-1.0 
mmol/L (CV 3.6% at 0.003 mmol/L and 2.5% at 0.437 mmol/L). 
Beta Hydroxybutyrate (D-3-Hydroxybutyrate) was measured quantitatively using the Stanbio 
Laboratory β-Hydroxybutyrate LiquiColor Assay Kit (Boerne, TX, USA) on the Beckman 
DxC800 Unicell (Brea, CA, USA) analyser using a spectrophotometric endpoint assay. 
Specimens were collected in lithium heparin tubes (#456083, Greiner Bio-One, 
Kremsmunster, Austria). The linearity of the assay is 0.0-4.0 mmol/L with the coefficient of 
variation (CV) 3.0% at 0.38 mmol/L and CV 2.1% at 1.38 mmol/L 
Patients were fed a weight based diet with a caloric goal of achieving 25 – 30 kcal/kg/d and 
a protein intake of 1 – 1.2 g/kg/d.  
Demographic data was collected including participant age, sex and primary diagnosis. 
Further clinical data including intracranial pressure (ICP), Glasgow Coma Scale (GCS) and 
nutrition (number of days of enteral nutrition) were also collected. 
With 33 included patients we had 80% power to detect a half standard deviation change in 
Ketone concentration over the 7 days of follow up assuming a 5% level of significance. A 
linear mixed model was used to estimate the change in Ketone concentration over the 7 
days of follow up. Within patient correlations were accounted for by the inclusion of random 
effects for each patient.  
4.4 Results 
38 patients with ABI were recruited into the study (22 F and 16 M) and followed for up to 7 
days (Table 4.1). The admission diagnoses included 19 CVA, 8 SAH and 11 with TBI. 22 
patients completed the full 7 days observations, 7 CVA, 7 SAH and 8 TBI. The overall 
mortality rate was 23%. During this period the mean highest ICP varied between 18 mmHg 
and 31 mmHg and CPP from 66 mmHg to 82 mmHg (Table 4.2). There was no evidence of 
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an association between BHB and ICP based on Spearman correlation (p=0.46 for ICP 
lowest and p=0.96 for ICP highest). 
Table 4.1. Demographic data of patients with acute brain injury    
 N Age Sex (m / f) LOS (hours) ICU Mortality 
(%) 
Total 38 60 ± 19 16 / 22 266 ± 250 23.7 
CVA 19 61 ± 19  179 ± 147 15.8 
SAH 8 64 ± 13  456 ± 418 12.5 
TBI 11 55 ± 21  277 ± 161 45.5 
All data were expressed as mean± standard deviation or number (percentage). 
CVA: Cerebrovascular accident; SAH: subarachnoid haemorrhage; TBI: traumatic brain injury 
Table 4.2. Clinical and biochemical observations measured daily over trial period 
 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
ICP (mmHg) 
 
20±10 18±6 22±14 24±13 25±11 31±17 25±13 
CPP (mmHg) 66±11  73±10  80±24  82±22 
BHB(plasma) 
(mmol/l) 
0.29 ±0.33 0.32±0.58 0.19±0.24 0.2 ±0.23 0.22±0.41 0.1 ±0.06 0.08±0.03 
Acetoacetate 
(plasma) 
(mmol/l) 
0.19 ±0.16 0.16±0.29 0.09 0.05 0.12±0.10 0.13±0.15 0.09±0.08 0.05±0.04 
Glucose(mmol/l) 8.26 ±5.52 8.25±2.31 8.3 ±2.04 7.87±1.61 8.18±2.04 8.10±15.9 8.17±2.36 
Lactate (mmol/l) 1.69 ±1.09 1.46±0.63 1.49±0.65 1.32±0.55 1.27±0.58 1.62 ±1.8 1.25±0.49 
pH 7.41 ±0.05 7.43±0.06 7.44±0.07 7.45±0.07 7.45±0.05 7.44±0.07 7.44±0.05 
HCO3(mmol/l) 22.67±3.24 23.7±3.45 24.9±6.14 25.3±3.76 25.8 ±3.8 25.8±4.08 25.8±3.58 
Na(mmol/l) 140±4.8 141±4.9 141±6.1 143±5.9 142±6.9 142±8.04 142±7.28 
Ag 6.5 ±3.0 5.4±2.45 5.6±3.15 10.6±2.05 6.5 ±2.7 5.9 ±3.30 6.5 ±2.7 
CPP: cerebral perfusion pressure; ICP: intracranial pressure; BHB: beta-hydroxybutyrate; Ag: anion gap 
During the study period, plasma BHB concentrations were increased initially but normalized 
by day 3 and acetoacetate concentrations remained within the normal range (normal BHB 
< 0.20 mmol/l, acetoacetate < 0.30 mmol/l). The change in BHB was significant (Table 4.3). 
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There was no statistically significant difference in BHB concentrations between genders a 
gender difference in BHB (P>0.05). More specifically there was insufficient evidence of a 
difference at baseline (P=0.24) or over time (P=0.085). Plasma lactate concentrations 
peaked at 1.69 mmol/l and glucose varied between 7.87 mmol/l and 11.21 mmol/l. There 
were 30 observations in 10 patients where BHB could be measured in both blood and CSF 
(in patients with SAH). There is no evidence of differences in blood BHB by diagnostic group 
(P=0.39) or evidence of interaction between trend over time and diagnostic group (P=0.19). 
When the data are averaged over patients there is weak evidence of correlation 
(Spearman’s rho = 0.62, P=0.054). 
Table 4.3 Trends over time based on mixed models analysis 
 Estimate SE P-value 
BHB -0.033 0.011 0.004* 
Acetoacetate -0.010 0.007 0.14 
pH 0.0076 0.0017 <0.0001* 
Lactate -0.044 0.032 0.16 
Glucose 0.21 0.21 0.32 
PaCO2 0.51 0.32 0.11 
PaO2 -3.7 0.91 <0.0001* 
Bicarbonate 0.62 0.081 <0.0001* 
Sodium 0.15 0.13 0.25 
Anion gap 0.11 0.34 0.76 
BHB: beta-hydroxybutyrate 
*P<0.05 
These results as shown in Table 4.3 suggest BHB and PaO2 decreased over the 7 days; pH 
and bicarbonate increased; but there was insufficient evidence to show changes over time 
for any other variable.  
The results in Table 4.4 were based on decomposing the time-dependent covariates (pH, 
bicarbonate, glucose) into components based on the mean values for each patient; and the 
differences within patients 141. There was no evidence of association between the time-
dependent covariates and acetoacetate and also between glucose and BHB but there was 
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evidence of associations between the differences in pH and bicarbonate within patients and 
BHB, however there was no evidence of association between the mean values of each 
patient for pH and bicarbonate, and BHB. There is therefore evidence that both pH and 
bicarbonate are associated with BHB but that this association is due to differences within 
patients and not differences between patients.   
Table 4.4 Correlations between parameters based on mixed models 
Outcome Predictor Estimate SE P-value 
BHB pH (mean) 
pH (difference) 
-0.99 
-1.27 
0.86 
0.53 
0.25 
0.018* 
BHB Bicarbonate (mean) 
Bicarbonate 
(difference) 
-0.0071 
-0.033 
0.013 
0.0091 
0.58 
0.0004* 
BHB Glucose (mean) 
Glucose (difference) 
-0.014 
0.00066 
0.015 
0.0038 
0.34 
0.87 
Acetoacetate pH (mean) 
pH (difference) 
-0.21 
-0.13 
0.58 
0.32 
0.71 
0.68 
Acetoacetate Bicarbonate (mean) 
Bicarbonate 
(difference) 
-0.0041 
-0.0054 
0.0083 
0.0052 
0.62 
0.31 
Acetoacetate Glucose (mean) 
Glucose (difference) 
0.0074 
0.011 
0.011 
0.0066 
0.50 
0.10 
BHB: beta-hydroxybutyrate 
*P<0.05 
Note that there were only 6 (3%) occasions when patients did not received nutrition. This 
occurred for 5 patients at day 1 and for 1 patient on day 2. Due to the small number of 
patients not fed over the follow up period this variable was not included in the analysis.  
4.5 Discussion 
The purpose of this study was to examine baseline ketone concentrations in blood and CSF 
following ABI. We noted a reduction in plasma BHB over the course of the study period with 
concentrations peaking at 0.32 ± 0.58 mmol/l on day 2 and subsequently decreased to 0.08 
± 0.03 mmol/l by day 7. This reduction was seen across all diagnostic groups. This finding 
may reflect a number of physiological changes during the acute phase of illness. Certainly, 
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catecholamine levels are raised following ABI. Termed “autonomic dysfunction syndrome” 
elevated catecholamine levels were initially described in SAH and stroke but also occur in 
patients with TBI. Raised catecholamine levels are associated with poor outcome and the 
use of Beta-blockers to limit secondary injury is associated with improved outcomes post 
TBI 142. This was confirmed by Tamaki et al who demonstrated significantly raised 
epinephrine and norepinephrine concentrations post SAH and the corresponding increase 
in ketones137. Despite only collecting data on admission and day 30, they noted significant 
decrease in ketone body concentrations which correlated with a decrease in plasma 
catecholamine concentrations.  
Catecholaminergic stress is a major trigger for ketogenesis and leads to partial degradation 
of long-chain fatty acids liberated from white adipose tissue and subsequent generation of 
ketone bodies. The other potential trigger for ketone production is glucopenia brought about 
by fasting1. It is not uncommon for delays to occur in the establishment of adequate nutrition 
in the critically ill population. The reasons are numerous but include delayed initiation of 
feeds and a tendency to initial absorption delays in the ABI population20. We postulated that 
the combination of catecholaminergic stress and inadvertent fasting was responsible for the 
initial rise in BHB.  
Ketone bodies can provide energy to the brain at times of glucose shortage and may 
displace glucose as preferred energy source in cerebral tissue following ABI. In fact, Owen 
et al demonstrated that ketone body uptake was sufficient to supply 70% of cerebral energy 
requirements 27. The optimal concentration of BHB is unknown although laboratory 
experiments suggest plasma concentrations of approximately 4.0 mmol/l or greater are 
required to protect against cerebral oxidative stress 143. Although controversial, a similar, 
plasma concentration is thought to be required to inhibit seizures in children with poorly 
controlled epilepsy 87. Our results suggest that post ABI, intrinsic concentrations of BHB are 
insufficient to provide significant cerebral energy augmentation. Exogenous BHB 
supplementation would be required to raise BHB concentrations to clinically significant 
concentrations.  
The blood brain barrier is relatively impermeable to ketones and BHB is transported into the 
CSF by a carrier protein which regulates the rate of uptake. Cerebral BHB concentrations 
are therefore affected by overall plasma concentrations and time. Previous animal research 
from our group noted that a continuous IV infusion of saline/BHB leads to a dose dependent 
increase in plasma and CSF BHB concentrations in healthy rats and that increases in brain 
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concentrations of BHB are dependent on plasma concentrations 144. Furthermore, we found 
a correlation between the final plasma, CSF and brain concentrations of BHB, suggesting 
that cerebral BHB concentrations are dependent on plasma and CSF.  
Of the current SAH patients we investigated, we were able to collect 30 matching 
plasma/CSF specimens noting a correlation coefficient of 0.62. The mean CSF 
concentration was 0.09 mmol/l. Lamers et al found a similar relationship between blood and 
CSF BHB in 58 children following a period of fasting (r=0.71). Similarly, Owens et al noted 
that the CSF ketone concentration was directly proportional to the blood ketone-body 
concentration in 8 obese patients undergoing a 21 day fast 30, 145. Owen noted relatively low 
blood (0.070 mmol/l) and CSF (0.042 mmol/l) ketone concentrations initially. However, after 
a 21 day fast, there was a significant increase in blood BHB (4.95 mmol/l) which was similarly 
reflected in the CSF (2.09 mmol/l). These and other studies confirm the relationship between 
blood and CSF BHB. Although starvation is an effective means of increasing blood ketones, 
the evidence suggests that early feeding improves outcome in critically ill patients 146. 
Therefore, in order to produce a sufficiently raised plasma concentration an external source 
of ketones will be required. 
Plasma (and subsequently CSF) ketones may potentially be increased by several means. 
Traditionally ketogenic diets, which consist of high fat, low carbohydrates in varying 
concentrations, have been utilized for this purpose. Most experience has been gained from 
using ketogenic feeds to control seizures in children with poorly controlled epilepsy28. 
Although generally unpalatable, ketogenic diets are fairly effective at increasing plasma 
ketone concentrations. There is far less evidence in the adult population, where these diets 
have proven less ketogenic. Ritter et al examined several ketogenic diets in an animal model 
of ischemia, one of which was subsequently evaluated in adult patients with TBI91. Although 
the difference between the ketogenic diet and control groups was significant, plasma BHB 
concentrations remained low, at less than 0.6 mmol/l, well below what may be considered a 
therapeutic level. Another option is to provide ketones intravenously as a salt. Pan and 
Blomqvist have demonstrated an increase in plasma and brain concentrations of BHB 
following an intravenous infusion 43, 132. Hiraide et al were able to increase ketone 
concentrations to 1.5 mmol/l with a 3 hour infusion of BHB at 25 umol/kg/l94. However, the 
high cost of producing intravenous ketone formulations makes the IV route uneconomical. 
More recently Kieran et al have demonstrated significant increase in plasma ketones 
following the oral administration of a ketone ester, with BHB reaching plasma concentrations 
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of up to 3.30 mmol/l 147. In the future, this may provide an effective and affordable means 
for inducing ketosis.  
This study has several limitations. Firstly, the high SD for BHB is due to 4 patients with 
particularly high values (>1 mmol/l). Three of those patients had cerebrovascular disease 
and the fourth patient had subarachnoid haemorrhage. It likely also reflects the relatively 
small sample size. Secondly, catecholamine levels were not measured. The only study of 
which we are aware comparing ketones and catecholamine levels in patients with SAH 
performed measurements on day 1 and 30 only. We therefore have no direct comparison 
over the shorter period. Certainly, it has been demonstrated catecholamine levels are initially 
high following TBI and then decrease steadily over the subsequent 7 days 138-140. Our results 
are similar to Ritter et al where ketone concentrations steadily decrease in their control group 
until about day 4 and then remained low until day 14 91. Thirdly, we did not record the total 
calorie intake per patient per day. We did however; observe that there were only 6 (3%) 
occasions when a patient wasn’t fed. The feeding regimens are fairly standard providing 25-
30 kcal/kg/d of energy and 1.0-1.2 g/kg/d of protein. As noted, the main determinant of 
ketogenesis is low insulin concentrations and high catecholamine levels. Although the 
average glucose concentrations remained above 7.5 mmol/l, insulin was not measured and 
its effects are unpredictable in the acute setting. Lastly, exogenous catecholamine 
administration was not recorded. Studies in health adults have demonstrated a correlation 
between exogenous catecholamine administration and ketone concentrations 148. It is 
therefore conceivable that this could play a role in ketogenesis in unstable ABI patients.  
4.6 Conclusion 
In this study, we have demonstrated that patients with ABI who are fed a standard diet fail 
to produce significant concentrations of ketosis intrinsically. Thus, to achieve elevated 
plasma concentrations of ketones, an external source of ketones is required. The results 
provide a basis to proceed to interventional studies of ketone supplementation in patients 
with brain injury. The challenge then is to design studies to demonstrate that; ketosis can be 
achieved using one of these formulations, and that the side effect profile is acceptable and 
finally, that outcomes can be improved. 
Prior to undertaking a study of ketone supplementation, it was necessary to understand the 
role of other potential cerebral energy substrates with the potential to replace glucose as the 
preferred energy source. We therefore undertook a review of current literature.  
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Chapter 5:  Novel metabolic substrates for feeding the injured brain 
5.1 Synopsis and citation 
 Aim:  
This chapter reviews the basics of cerebral energetics and examines alternative substrates 
capable of meeting cerebral energy requirements in both health and disease. 
Citation:   
This chapter is based on a publication reviewing the use of alternate substrates capable of 
meeting cerebral metabolic requirements. Figures and tables have been inserted into the 
text at different positions and the numbering of pages, figures and tables has been 
adjusted to fit the thesis. The references have been incorporated with the other references 
of the Thesis.   
The original manuscript was: 
White H, Kruger P, Venkatesh B. Novel metabolic substrates for feeding the injured brain. 
In Vincent JL, ed. Yearbook of Intensive Care and Emergency Medicine, 2017. Pa: 
Springer-Verlag; 2017: 477-487. Associate Professor Kruger and Professor Venkatesh 
assisted with preparation of the original manuscript. 
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5.2  Introduction 
Brain injury is common with a high mortality and morbidity with implications for both society 
and individuals, in terms of cost, loss of production, and long term impairment 149. The 
cellular and molecular events initiated by cerebral injury are complex, restricting the 
precision of characterization into primary, secondary and long term as the duration of 
pathogenic events are variable and can overlap. Following injury, cellular energetics play a 
vital role in maintaining cerebral homeostasis 150. A better understanding of the impact of 
substrate supply on the injured brain may help improve management following brain injury 
and provide novel therapeutic options.  
The adult brain consumes approx. 20% of basal metabolism, most of which is provided by 
the oxidation of 100-120 g of glucose/24 hrs 143. However, in times of starvation or injury, 
the primary cerebral metabolic substrates may alter. Following TBI, brain injury a number of 
biochemical changes take place in the brain which diverts the processing of glucose via the 
normal pathways. 
The purpose of this review is to examine cerebral energetics and alternative substrates 
capable of supplying cerebral energy requirements (Table 5.1).  
Table 5.1 Potential substrates for enhancing cerebral energy supply. 
Substrate Proposed Mechanism of action 
Ketones BHB is more energy efficient then glucose  
Increase in free energy of ATP hydrolysis 
Increase in intermediary metabolites delivered to 
citric acid cycle 
Protect against glutamate mediated apoptosis by 
attenuation of reactive oxidant species 
Enhancement of GABA mediated inhibition 
Increase in cerebral blood flow 
Lactate Sparing of cerebral glucose metabolism 
Regulation of cerebral blood flow 
Protects neural tissue against excitotoxicity as it 
attenuates neuronal death  
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BCAAs Limited protein loss from skeletal muscle 
Contribute to synthesis of both inhibitory and 
stimulatory neurotransmitters 
Lower cerebral levels of serotonin and 
catecholamines 
Supplement intermediates in TCA cycle 
Triheptanoin Replenish TCA cycle intermediates 
Improvement in cerebral energetics 
BHB (beta-hydroxybutyrate), GABA (gamma-aminobutyric acid), BCAA (branch chain amino acids) 
5.3  Cerebral Metabolism 
Despite comprising only 2% of total body weight, the brain receives 15% of cardiac output 
and can use up to 20% of total body oxygen 151. The main cerebral energy source is derived 
from ATP produced almost completely from the oxidative metabolism of glucose. As such, 
25% of total glucose is metabolised by the brain. During starvation however, hepatic 
glycogen stores rapidly become exhausted. After several days, brain glucose is produced 
as a result of gluconeogenesis from amino acids derived from muscle metabolism 152. From 
a week onward however, hepatic gluconeogenesis decreases and ketone bodies become 
the dominant fuel source for the brain (Figure 5.1).   
 
Figure 5.1 Ketones as an alternative cellular fuel source 
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Ketone bodies added to glucose fundamentally alter mitochondrial metabolism. When added to glucose, a 
physiological level of ketone bodies reduces the mitochondrial NAD couple, oxidizes the co-enzyme Q couple, 
and increases metabolic efficiency. These changes are shown on the right side of the figure. The arrows 
illustrate the effects of ketone bodies compared to glucose alone. Ketone bodies provide an alternative 
metabolic fuel which can act during blockade of glycolysis.  
Reprinted by permission from John Wiley and Sons: IUBMB Life Veech et al 51:241-247, copyright 
2001 
The injured brain 
Following injury, a number of biochemical changes take place in the brain which diverts the 
processing of glucose via the normal pathways. Disruption of ionic equilibrium shortly 
following traumatic brain injury (TBI) requires energy to correct, reflected by an initial 
increase in cerebral glucose uptake 153. This is followed by a prolonged period of glucose 
metabolic depression. Further disruptions include; shunting of glucose through the pentose 
phosphate pathway, increase in production of reactive oxidant species and DNA damage 
and inhibition of glycolytic processing of glucose (See Figure 5.2) 150. As such, other 
substrates including ketones may provide the injured brain with much needed energy. 
 
Figure 5.2 Sequence of cerebral metabolic changes following traumatic brain injury 
Reprinted by permission from Elsevier Publishers Ltd: Drug Discovery Today. Jain K 13:1082-1089, copyright 
2008 
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Studying cerebral metabolic dysfunction 
The metabolic dysfunction resulting from TBI has been extensively studied. In general, injury 
is still classified as primary, occurring at time of injury and secondary, a result of complex 
pathological processes occurring hours to days post injury. Experimental studies have 
revealed a number of changes including disruption to cellular membranes and homeostasis, 
release of excitatory neurotransmitters including glutamate, impaired mitochondrial function 
and generation of free radicals151, 154-156. Mitochondrial failure further exacerbates the 
cerebral energy deficit leading ultimately to apoptosis and cellular death. Much of the current 
research is aimed at restoring failing cerebral metabolic pathways and providing 
supplements to augment cerebral energy supply.  
A number of techniques are employed to investigate both the underlying metabolic 
perturbations following TBI and impact of substrate supplementation in these patients 153. 
Arterio-venous gradient studies have investigated the cerebral metabolic rate of glucose, 
the uptake of a number of precursors including lactate, fatty acids, essential amino acids 
and ketones 157-159. Although simple to perform, they lack the precision and the ability to 
differentiate between injured from normal cerebral tissues. Microdialysis improves upon 
these limitations providing continuous sampling from localised areas of interest with the 
opportunity to analyse a variety of molecules 158. Features associated with adverse 
outcomes include high concentrations of lactate, high lactate/pyruvate ratio and both high 
and low glucose concentrations 160, 161. Despite these findings, microdialysis is still an 
experimental technique. Parameters may be difficult to interpret and owing to the focal 
nature of the findings, their impact on treatment options is uncertain.  
Positron emission tomography (PET) scanning has the advantage of being non-invasive, 
quantitative and dynamic. PET imaging studies using labelled substrates including 2-deoxy-
D-glucose have provided valuable information regarding glucose metabolism, confirming the 
relative depression in glucose utilisation post TBI 162. Newer techniques however allow PET 
studies of labelled β-hydroxybutyrate and acetoacetate to determine the metabolic fate of 
ketone bodies in the brain and other tissues 163. To date studies have confirmed that in the 
brain, ketosis reduces glucose utilization and increases ketone oxidation. With the steady 
increase in the availability of tracers, more research into cerebral metabolism will improve 
our understanding of these pathways.  
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Magnetic resonance imaging (MRI) techniques (such as magnetic resonance spectroscopy 
(MRS)) can be useful in detecting the uptake and metabolism of a number of substrates 
including N-acetylaspartate, choline-containing phospholipids, creatine and 
phosphocreatine, lactate, myo-inositol, glutamate, Ketones, gamma-aminobutyric acid 
(GABA), and lipids 164. An important advantage is their ability to provide biochemical 
information without the need for tracers and non-invasively. A number of studies have 
utilized MRS to provide data on cerebral metabolism of both lactate and BHB during 
starvation and following TBI 42. The main limitation of the technique is the need to transfer 
critically ill patients to the MRI scanner and the associated risks.  
5.4  Potential substrates capable of maintaining cerebral energetics 
Neuroprotective effects of ketones   
Ketogenesis is the process by which ketone bodies are produced via fatty acid metabolism 
in the liver 1. Ketones or ketone bodies are by-products of fat metabolism. They consist of 
four carbon units where part of the molecule contains a carbon-oxygen bond (C= O). They 
provide an alternative pathway for the metabolism of acetyl CoA through the ß-oxidation of 
free fatty acids. Acetoacetate is the central ketone body. Subsequently acetoacetate can be 
reduced to BHB by β-hydroxybutyrate dehydrogenase in a NADH-requiring reaction. 
In health, glucose is the major fuel for human brains. During times of starvation however, 
the brain has the capacity to adapt to the use of ketones as its major energy source. Once 
glucose stores are depleted, supplying sufficient glucose to support brain metabolic 
requirements from protein alone would lead to death in about 10 days. However there are 
reports of survival for 50–70 days in people undergoing prolonged fasting and ketones play 
a key role 152. During periods of ongoing starvation, an average size person produces about 
150 g of ketone bodies per day, capable of supply 70% of cerebral metabolic requirements 
27. Ketones therefore play a critical role in human evolution. 
Aside from their evolutionary benefits, ketones may have neuroprotective effects as they 
represent an alternative fuel for both the normal and the injured brain 4, 51, 117. There are 
unique properties of ketone metabolism that may make it a more suitable cerebral fuel under 
various neuropathologic conditions:  
1. Ketones are more energy efficient than glucose 
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2. Ketones protect against glutamate-mediated apoptosis 
3. Ketones enhance GABA-mediated inhibition 
4. Cerebral ketone metabolism alters cerebral blood flow  
Exogenous ketone supplementation has been examined in a wide range of animal and 
human models of neurological disorders including autism, Alzheimer’s disease, migraine, 
strokes, hypoxic-ischemic encephalopathy, Parkinson disease, amyotrophic lateral 
sclerosis, epilepsy and traumatic brain 165, 166. More recent studies have examined the use 
of these diets in the management of brain tumours based on the fact that altered glucose 
metabolism may have anti-tumour effects 167. Most human research has looked at ketone 
supplementation in children for the management of refractory epilepsy. Although initially 
contentious, there is now good evidence supported by two randomized controlled trials that 
ketogenic diets in children improve seizure control 99, 168.  The evidence in adults is less 
compelling but no good studies exist. 
Non-esterified fatty acids (NEFA) as a cerebral energy supplement  
The ability of ketones to improve cerebral energy metabolism is not shared by other fatty 
acid containing compounds. Despite being hydrogen rich, fatty acids are utilized poorly by 
the brain as fuel and may have a number of deleterious properties including the induction of 
apoptotic pathways 169. Although highly protein bound, the slow passage of NEFA across 
the blood brain barrier (BBB) does not appear to be the cause of poor fatty acid oxidation. 
Certainly, there is evidence that NEFA may actually damage the BBB by enhancing 
oxidative stress in endothelial cells. Furthermore, despite the rapid oxidation in peripheral 
tissues, NEFA is metabolised slowly by the brain and appears to require more oxygen than 
glucose, further exacerbating the hypoxic environment of the injured brain 170. The poor anti-
oxidative defences in neurons may be considerably overwhelmed by the rapid accumulation 
of superoxides following β-oxidation of NEFA. Thus, the many benefits associated with 
ketone supplementation are not shared by free fatty acids which may prove detrimental in 
the TBI population.  
Lactate as a glucose sparing fuel 
Lactate is a dead-end metabolite of its redox partner, pyruvate 171. In mammals, 
physiological concentrations may vary between 0.05 – 5 mmol/l. Lactate is metabolised via 
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lactate dehydrogenase with the extent and direction of the reaction determined by the 
NAD/NADH(H) ratio. Along with pyruvate, it forms the initial substrate for the tricarboxylic 
acid cycle and subsequently is critical for cellular energetics 172. Lactate has two optically 
active forms, L(-) and D(+). The predominant physiological form is L(-) and the metabolic 
effects resulting from metabolism of the 2 forms differs significantly. Lactate is actively 
transported across plasma membranes including red cells, kidney and liver and somewhat 
slower in the heart skeletal muscle and the brain.  
Evidence suggests that lactate can act as an energy source for the brain, especially during 
periods of substrate deficiency. Data confirms a significant increase in brain lactate following 
2-3 days of fasting 42. This may arise from a shift in lactate metabolism following the shift 
toward ketone oxidation. Others suggest a continuous production of lactate through 
glycolysis possibly via a complex interaction between astrocytes and oligodendrocytes (the 
so call astrocyte-neuron lactate shuttle) 173.  
Studies in TBI patients seem to support a role for hypertonic lactate solution in reducing 
intracranial pressure (ICP) and demonstrate positive effects on cerebral energetics. 
However, this may depend on the baseline cerebral metabolic state 174. Studies in animals 
confirm the supposition that lactate may improve outcomes in TBI. Animal models of both 
trauma and hypoxic injury have demonstrated a reduction in functional deficits, decrease in 
lesion volumes and CBF augmentation 175, 176. Only a small number of studies have involved 
humans. Glenn et al demonstrated that peripheral lactate production accounted for approx. 
70% of carbohydrate consumed for energy production by the traumatized brain and 
suggested lactate should be supplemented to compensate for decrease in glucose cerebral 
metabolism 177. To assess the impact of exogenous lactate on cerebral energy metabolism, 
Bouzat et al administered hypertonic lactate (HL) to 15 patients with TBI 178. Using cerebral 
microdialysis, they demonstrated an increase in lactate, pyruvate and glucose and noted a 
concomitant decrease in glutamate and ICP. They concluded that HL solution had a positive 
effect on cerebral energetics and may be a useful therapeutic intervention. Similarly, Ichai 
et al demonstrated HL to be more effective at lowering and maintaining ICP when compared 
with other hypertonic solutions 179. By sparing cerebral glucose and decreasing ICP, HL may 
provide an alternative means of controlling ICP while improving cerebral energy metabolism. 
Branch-Chain amino acids and recovery post TBI                                                                         
The branch-chain amino acids consist of leucine, isoleucine and valine. They account for 
approximately 35% of essential amino acids and 14% of amino acids in skeletal muscle. 
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BCAA’s, while nutritionally essential cannot be synthesized by humans and must be 
supplied in the diet. They have been demonstrated to impact positively on protein 
metabolism by inhibiting muscle breakdown and promoting muscle and hepatic protein 
synthesis 180. They are essential in the nutritional support of the critically ill. BCAA’s impact 
on the production of cerebral neurotransmitters in several ways and contribute to the 
synthesis of both inhibitory and stimulatory amino acids 181. They are essential for 
synthesis of glutamate, which has been implicated in excess cellular damage following 
TBI, but also GABA, considered to be an inhibitory neurotransmitter and therefore 
potentially neuroprotective 182. Furthermore, by competing for transport across the blood 
brain barrier, BCAA’s lower cerebral concentrations of tryptophan, tyrosine and 
phenylalanine and therefore indirectly, concentrations of serotonin and catecholamines. 
They can also supplement intermediates in the citric acid cycle, potentially improving 
cerebral energetics.  
BCAA have been shown to improve cognitive function in a number of conditions. In animal 
studies, BCAA supplementation provided a sustained improvement from in cognitive 
function in a mouse model of TBI 183. In healthy, exercising people, BCAA’s lower exertional 
and mental fatigue. Patients with hepatic encephalopathy benefit from BCAA 
supplementation with improved mental status, asterixis orientation, speech and writing. In 
an observational study of the TBI population, Vuille-Dit-Bille et al demonstrated that raised 
levels of the aromatic amino acids (AAA) were associated with decreased ICP and increased 
jugular venous oxygen saturation as compared to BCAA’s 182. One small study (n = 20 ) 
from Ott et al demonstrated that TBI patients administered BCAA maintained a positive 
nitrogen balance but data on morbidity and mortality were not provided 184. Aquilani et al 
conducted 2 small studies (total of 42 patients in intervention group and 39 in control) 
examining the benefits of BCAA supplementation on cognitive function in the recovery 
period post TBI 185, 186. They were able to demonstrate a significant improvement in the 
Disability Rating Scale in patients receiving the supplements. However, the BCAA’s were 
administered anywhere from 19 – 140 days following injury, and therefore the studies do not 
address their use in the acute setting. There is therefore currently no strong evidence 
supporting BCAA use following acute brain injury. 
Triheptanoin and anaplerosis 
Anaplerosis, is the process by which intermediates in the TCA cycle are replenished 
involving the carboxylation of pyruvate and propionyl-CoA. Anaplerotic molecules may 
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include amino acids and odd chain fatty acids. Pyruvate carboxylase appears to be the main 
anaplerotic enzyme in the brain. Cerebral ATP production is largely dependent on a 
functioning TCA cycle. Evidence suggests that during neurological injury, including seizures, 
energy production may be compromised. Therefore, improving cerebral energetics may be 
an effective therapeutic target.  
Triheptanoin was discovered by Roe et al as an oral anaplerotic treatment for metabolic 
disorders 187. It is a triglyceride of heptanoate (C7 fatty acid) capable of being metabolized 
by β-oxidation to provide propionyl – CoA which can subsequently be carboxylated to 
produce succinyl-Coa, and entering the TCA cycle. Triheptanoin is a tasteless oil, which 
may enter the brain directly or following the following metabolism in the liver to C5 ketone 
bodies β-hydroxypentanoate and β-ketopentanoate. These may subsequently be taken up 
in the brain through MCT transporters 188. The result is an increase in acetyl-CoA and ATP 
production.  
Triheptanoin has been proven effective in patients with different metabolic problems 
including cardiomyopathy and rhabdomyolysis in acyl-CoA dehydrogenase deficiency, 
pyruvate carboxylase deficiency and carnitine-palmitoyltransferease II deficiency. Several 
studies involving animal models of epilepsy found triheptanoin to be effective as an 
anticonvulsant 189, 190. Adenyeguh et al found that triheptanoin administered to patients with 
early stage Huntington’s disease was able to partially correct the abnormal brain energy 
profile noted in these patients 191. Efforts are underway to further evaluate the anticonvulsant 
effects of triheptanoin and to understand its clinical potential for management of epilepsy 
and other brain disorders 189, 192. 
5.5  Challenges in developing new fuel substrates for the injured brain 
While several examples exist that might make metabolic sense in the injured brain, the 
impact of their therapeutic use and other aspects of systemic metabolism remain to be seen. 
Probably the most researched substrates are ketones. Adverse effects related to chronic 
oral intake are well described from the paediatric literature. Less is known about the 
consequences of administering high doses in the acute brain injury population. Furthermore, 
there are a number of potential routes of administration which may present their own 
challenges. Several papers have looked at the administration of BHB as a sodium salt via 
the intravenous route 80, 88, 144. This allows for a rapid increase in peripheral BHB 
concentrations although long term infusions lead to an increase in pH. The effects of this on 
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ICP have not been investigated to date. Other potential routes of administration include 
various ketogenic enteral formulations, the commercial product KetoCal® and more 
recently, as a ketone monoester 193.  
Lactate can be administered as an iso or hypertonic formulation. The benefits of hypertonic 
solutions in the head injury population are well described 194. In general, the likelihood of 
potential side effects including hypernatremia, increased osmolality and metabolic alkalosis 
will depend on the formulation provide and the length of time. Bouzat et al administered a 
hypertonic solution of lactate to head injury patients and did not find any change in 
physiological variables including PaCO2 however, the infusion only ran for 3 hours  178.  
The impact on systemic glucose metabolism is variable. Ketone administration is associated 
with decreased glucose concentration 91. Lactate is thought to produce a glucose sparing 
effect in the brain while NEFA may actually lead to  hyperglycemia  195. BCAA seem to 
stimulate insulin production in the short term but may lead to insulin resistance following 
long term administration 185.  
Consideration should also be given to the impact of organ dysfunction such as liver or renal 
failure when considering substrate supplementation. BCAA have been extensively studied 
in critically ill patients and appear to be well tolerated and certainly are demonstrated to be 
protein sparing 88. Similarly, NEFA may have a positive impact in critical illness although as 
previously noted, may be deleterious in the brain injury population 195. Ketones and lactate 
may accumulate and potentially lead to metabolic derangements such as systemic 
academia if liver/renal function markedly impaired, leading to an inability to metabolise these 
substrates.  
It is therefore necessary to consider the implications of supplementing substrates in terms 
of other potential metabolic effects and in the setting of major metabolic derangements.  
5.6  Conclusion 
In healthy individuals, glucose is the main substrate for cerebral energy production. 
However, it is clear that in the damaged brain, a significant alteration takes place in 
metabolic pathways and other substrates may become more important. Of the various 
potential substances investigated, ketones have received the most in-depth study and would 
appear to be an excellent alternative to glucose. Research into the field of cerebral 
energetics however, is still in its infancy. More effort is required to determine which metabolic 
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substrate or combinations of these might provide the damaged brain with the optimum 
energy requirements. 
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Chapter 6:  Systematic Review of the use of ketones in the management 
of acute and chronic neurological disorders 
6.1 Synopsis and citation 
Background:  
Ketosis is currently being utilized as treatment option in paediatric patients with resistant 
epilepsy. However, the evidence for efficacy in adult epilepsy and other neurological 
conditions is lacking.  
Aims: 
The purpose of this systematic review is to examine the evidence for inducing ketogenesis 
in adult humans with neurological and neurosurgical disorders, both acute and chronic  
Design:  
We conducted a literature review through electronic databases, including Medline, the 
Cochrane Library and PubMed.  
Key Findings:  
14 publications met the selection criteria for inclusion into this study. Study subjects included 
Alzheimer’s disease, severe refractory status epilepticus, intracranial neoplasms, traumatic 
brain injury and idiopathic Parkinson’s disease. Although studies suggested ketosis may be 
beneficial, interpretation is limited by poor quality of evidence. 
Conclusions:  
Ketone administration may prove beneficial in the management of a number of neurological 
conditions. Better quality studies are required before firm conclusions can be drawn 
Citation: 
This chapter is based on a publication reviewing the evidence for inducing ketogenesis in 
adult humans with neurological disorders. Figures and tables have been inserted into the 
text at different positions and the numbering of pages, figures and tables has been adjusted 
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to fit the thesis. The references have been incorporated with the other references of the 
Thesis.  
The original manuscript was “Systematic review of the use of ketones in the management 
of acute and chronic neurological disorders” by H White, K Venkatesh and B Venkatesh was 
published in Journal of Neurology, and Neuroscience, April 27, 2017. 
Contribution: 
H White and K Venkatesh performed all data collection, collation and review of data and 
completion of manuscript. B Venkatesh reviewed manuscript and assisted with completion. 
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6.2   Introduction 
Neurological disorders are common and sometimes catastrophic, leading to significant 
morbidity and mortality. At a pathophysiological level, many of these disorders are 
characterised by a disruption of normal metabolic pathways 130. Following injury, cellular 
energetics play a vital role in maintaining cerebral homeostasis. The adult brain consumes 
approximately 20% of basal metabolism, most of which is provided by the oxidation of 100-
120g of glucose over 24 hours 8. However, during times of starvation or injury, the primary 
cerebral metabolic substrates may alter. Ketones may represent an alternative fuel in these 
instances. 
There are unique properties of ketone metabolism that may make it a more suitable cerebral 
fuel under various acute and chronic neuropathologic conditions 51, 58 (see chapter 1). 
Induction of ketosis has therefore been attempted in various neurological states. Ketosis 
may be induced via the intravenous or enteral route. However, largely owing to the high cost 
of producing intravenous IV solutions, most researchers have employed enteral feeding 
formulations. Ketogenic diets were initially employed in the management of refractory 
epilepsy in children 196, 197. This came about from the observation that starvation states were 
associated with improved seizure control 198. Until recently, the benefits of the ketogenic diet 
were contentious and restricted to specialist units such as John’s Hopkins and Harvard 
medical school. However, the benefits of the ketogenic diet for seizure control in children 
have now been demonstrated in two randomized controlled trials 99, 168. The evidence in 
adults however is far less clear with case reports and case series dominating the literature 
199-201. 
Ketogenic diets have been examined in a wide range of animal and human models of 
neurological disorders including autism, Alzheimer’s disease, migraine, strokes, hypoxic-
ischemic encephalopathy, Parkinson disease, amyotrophic lateral sclerosis, and traumatic 
brain injury 56, 165, 202, 203. More recent studies have examined the use of these diets in the 
management of brain tumours based on the fact that altered glucose metabolism may have 
anti-tumour effects 167.  
Most published research has investigated the role of ketogenesis in children for the 
management of refractory epilepsy 196, 204. Recent reviews have examined the use of 
ketogenic diets in the management of seizure disorders in adults 205-207. The purpose of this 
systematic review is to examine the evidence for inducing ketogenesis in adult humans with 
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neurological and neurosurgical disorders, both acute and chronic. We have excluded 
seizure disorders (other than status epilepticus) as this was recently reviewed by others 204.  
6.3   Methods 
Data sources 
We conducted a literature review through electronic databases, including Medline, the 
Cochrane Library and PubMed. Additionally, we performed a search through 
www.clinicaltrials.gov to check for new or ongoing studies. Our search was focussed using 
the following MeSH terms: ketones, ketonaemia, B-hydroxybutyrate, ketogenic diet, adults, 
brain trauma, traumatic brain injury, status epilepticus, carbohydrate-free diet, 
neurodegenerative disease, Parkinson’s disease, dementia, Alzheimer’s disease, mild 
cognitive impairment, intracranial bleed and subarachnoid haemorrhage. 
We limited our search to papers published between January 1st, 1980 and June 30, 2016. 
We further limited our search to include only studies involving adult humans (over the age 
of 18).  
Study selection 
Two authors (HW and KV) performed the literature search as per the parameters listed 
above and compiled the relevant studies. Discrepancies were resolved by mutual 
discussions. Studies were selected if they were trials assessing ketosis in adult humans with 
current neurosurgical or neurological disorders. Both HW and KV were in consensus that 
for the purpose of this study, studies would be included if they assessed ketogenic diet, 
ketone supplementation, carbohydrate-free diet, induction of ketosis, or markers of ketone 
biochemistry in the study population.  
Studies were only included if they were original trials or case reports; they were excluded if 
they were reviews, meta-analyses or letters to the editor. Furthermore, studies were 
excluded if they were not written in English. 
Definitions 
Neurosurgical disorders were defined as traumatic brain injury, space-occupying lesions and 
any type of intracranial haemorrhage. Neurological disorders included cerebrovascular 
Systematic Review of the use of ketones in the management of acute and chronic neurological disorders 
70 
accidents, status epilepticus, and any neurodegenerative conditions where the primary 
pathology was occurring within the brain.  
6.4  Results 
Study selection 
From the literature search, we identified 14 publications that met the selection criteria for 
inclusion into this study (Figure 6.1). These are listed and summarised in Table 6.1 below.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Evaluation of papers for inclusion into this review 
Study characteristics 
Of the 14 publications, 3 were randomised controlled trials, 10 were case series (6 
prospective and 4 retrospective) and one was a non-randomised placebo control trial. The 
study populations of the 143 studies were as follows: 4 assessed patients with either mild 
cognitive impairment or Alzheimer’s disease, 5 investigated patients with severe refractory 
 
548 potential papers identified and screened after 
literature search using defined search terms 
 
Database 
Medline     138 
PubMed     378 
Cochrane Library    0 
www.clinicaltrials.gov   0 
Papers excluded (n = 211) 
Full-text papers excluded (n = 247) 
Papers after duplicates removed (n = 472) 
Papers after filters applied (n = 261) 
Full-text papers assessed for eligibility (n = 261) 
Total number of papers included for review in this 
study (n = 14) 
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status epilepticus, 32 evaluated patients with intracranial neoplasms and there was one 
study each in patients with traumatic brain injury and idiopathic Parkinson’s disease.  
In each study, the investigators aimed to induce hyperketonaemia either via carbohydrate 
restriction, or implementation of a ketogenic diet, or via the administration of oral ketogenic 
compounds (OKC). The OKCs were all high in lipids with low proportion of carbohydrates. 
Mild cognitive impairment and Alzheimer’s disease 
Four studies investigated the role of ketone supplementation in patients with either mild 
cognitive impairment (MCI) or Alzheimer’s disease (AD). Henderson et al. and Reger et al. 
both compared the effects of an OKC on memory and cognition compared to placebo, in 
double-blind trials 97, 208. In both trials, higher plasma ketone concentrations were associated 
with improvements in memory and cognitive function. Subanalysis in the cohorts was 
performed to assess for the Apolipoprotein-E4 (APO-4) status of the patients (APO-4 
positivity is a mutation associated with increased risk of developing Alzheimer’s disease).  
In both studies, APOE-positive status was associated with a reduced response to ketone 
supplementation. Krikorian et al. compared a low carbohydrate diet with a carbohydrate-rich 
diet in adult patients with MCI, and assessed each diet’s effects on cognitive function 209. 
The group in the low-carbohydrate diet arm had improvements in their memory compared 
to the other group, however there was no significant difference in executive cognitive 
function between the groups. Newport et al. report a case study of an adult patient with AD 
who was commenced on an oral ketone ester to stimulate ketosis and to assess the effects 
of this on cognitive function 210. Improvements were noted in the patient’s cognitive 
performance (however not assessed objectively, with additional amelioration in social and 
self-care functions). 
Traumatic brain injury 
Only 1 study investigated the role of ketosis in adult patients with traumatic brain injury. It 
investigated whether sufficient caloric intake could be met with a low carbohydrate diet in 
patients with TBI (compared to standard nutrition), and whether there were significant 
adverse effects between the two groups 91. Patients in the low carbohydrate arm received 
adequate dietary calories without hypoglycaemia.
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Table 6.1 Summary of studies selected for inclusion into this review 
Study Author, year Type of study Population Number Intervention Primary endpoint Main findings 
1 
 
Cervenka et al., 
2011 221 
Case report Adult patient 
with SRSE 
1 Administration of 
enteral KD after 58 
days of SRSE 
To assess whether 
administration of 
enteral KD may be 
effective in SRSE 
Administration of enteral KD to 
adult male patient after 58 days of 
SRSE was associated with 
improvement in clinical and 
electroencephalographic seizure 
activity. Patient able to be weaned 
off parenteral anticonvulsants. No 
significant adverse effects 
reported related to KD. 
2 
 
Champ et al., 
2014 217 
Retrospective 
case series 
Adult patients 
with GBM 
53 Ketogenic diet vs. 
normal diet in 
patients with GBM 
To assess 
biochemical profile 
and toxicity of KD in 
patients with GBM 
6 out of the 53 patients reviewed 
trialled the KD. There were no 
episodes of hypoglycaemia 
associated with the KD and there 
did not appear to be any issues 
related to toxicity.  
3 Henderson et 
al., 2009 208 
Randomised, 
double blind, 
placebo-
controlled 
multicentre trial 
Adult patients 
with mild-
moderate AD 
152 OKC vs. placebo 
over 90 days 
To assess whether 
oral ketogenic 
compound could 
improve cognitive 
performance 
compared to 
placebo 
Administration of oral ketogenic 
compound caused increased 
serum levels of B-hydroybutyrate 
and significantly improved 
cognitive scores compared to 
placebo. Reduced response to 
oral ketogenic compound in 
APOE4+ patients.  
4 Krikorian et al., 
2012 209 
Randomised-
controlled trial 
Adults with 
MCI 
23 High CHO diet vs. 
low CHO diet over 6 
weeks 
 
 
To assess 
differences in 
cognitive function 
between patients on 
high CHO diet and 
low CHO diet 
Improved neurocognitive function 
was observed in the low CHO diet 
arm. Low CHO diet was 
reasonably well-tolerated however 
long-term feasibility was 
questionable 
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Study Author, year Type of study Population Number   Intervention Primary endpoint Main findings 
5 Nam et al.,  
2011 212 
Retrospective 
case series 
Patients with 
SRSE 
5 (1 adult 
and 4 
children) 
Administration of KD 
in patients with RSE 
over course of 
admission 
To assess the 
efficacy and safety 
profile of the KD in 
patients with RSE 
In the adult patient, there was 
complete resolution of SRSE 
within one month and return to 
normal function, with nil adverse 
effects reported in this patient 
6 Newport et al., 
2015 210 
Singe-patient 
case study 
Patient with 
younger-onset 
AD 
1 Administration of 
OKC over 20 
months 
Compare cognitive 
function pre and 
post implementation 
of OKC as per 
Administration of OKC was 
deemed safe, convenient and 
tolerable. Improved cognitive 
function and activities of daily 
living were observed in the 
patient. However, nil discussion of 
pre and post formal cognitive 
function testing scores.  
7 Reger et al., 
2004 97 
Double-blind 
placebo-control 
trial 
Adult patients 
with AD or MCI 
20 Administration of 
either OKC or 
placebo 
To compare the 
effects of increased 
ß-OHB on memory 
and cognitive 
function, compared 
to placebo. Also to 
assess effect of ß-
OHB on patients 
with APOE genotype 
vs. those without. 
Administration of OKC was 
associated with improved memory 
and cognitive function, compared 
to placebo. However, it was noted 
that patients positive for APOE 
genotype were less responsive to 
OKC than those who were 
negative for the gene. 
8 Reiger et al., 
2014 216 
Prospective 
case-control 
pilot study 
Adult patients 
with recurrent 
GBM 
20 Administration of 
low carbohydrate 
diet over 16 weeks 
To assess feasibility 
of the KD as judged 
by percentage of 
patients who 
discontinued diet 
Over the study time period, 17 out 
of 20 (85%) of patients were able 
to adhere to the KD. No significant 
adverse outcomes were reported 
in patients.  
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Study Author, year Type of study Population Number Intervention Primary endpoint Main findings 
9 Ritter et al., 
1996 91 
Randomised 
open-label 
control trial 
Adult patients 
with traumatic 
brain injury 
20 Administration of 
either OKC or 
normal diet 
Evaluate the 
biochemical 
parameters 
associated with 
administration of the 
OKC compared to 
those in patients on 
a normal diet, 
particularly 
assessing the 
glycaemic profile. 
Patients fed on the normal diet 
had higher arterial glucose 
concentrations compared to the 
group on the OKC diet. Arterial 
ketone concentrations were 
significantly higher in the OKC 
group than the normal diet group. 
There was insufficient power to 
draw conclusions on neurological 
outcomes with either group. 
10 Schwartz et al., 
2015 215 
Case studies 
with literature 
review 
Adult patients 
with GBM 
2 Administration of an 
energy-restricted 
KD over 12 weeks 
Assess the efficacy 
of KD in treating 
malignant gliomas, 
and to assess the 
safety and feasibility 
of a ketogenic diet.  
The two patients studied in the 
trial showed progression of their 
tumours while on the ketogenic 
diet. The ketogenic diet was 
deemed to be safe without major 
side effects and ketosis was easily 
inducible with ketogenic diet. 
11 Strzelczyk et al., 
2013 213 
Retrospective 
case study 
Adult patient 
with SRSE 
1 Intravenous 
administration of KD  
To assess the 
efficacy and safety 
profile of intravenous 
KD in treating SRSE 
Administration of intravenous KD 
was associated with resolution of 
SRSE and was a safe and 
feasible option for management of 
SRSE. 
12 Thakur et al., 
2014 201 
Retrospective 
case series 
Adult patients 
with SRSE 
10 Administration of a 
KD  
Assess the effects of 
a KD on timing of 
resolution of SRSE  
9 out of 10 patients achieved 
ketosis, with all 9/10 achieving 
resolution of SRSE within median 
of 3 days of starting KD.  
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Study Author, year Type of study Population Number Intervention Primary endpoint Main findings 
13 Vanitallie et al., 
2005 211 
 
Prospective 
case series 
 
Adult patients 
with idiopathic 
PD 
7 Home-prepared KD 
over 28 days 
Assess the feasibility 
of patients preparing 
a KD themselves 
and adhering to it 
5 out of the 7 patients were able to 
prepare the KD themselves and 
adhere to it over the study course. 
There appeared to be some 
degree of improvement in 
symptoms of PD but insufficient 
sample size to draw conclusions 
on this. 
14 Wusthoff et al., 
2010 214 
Prospective 
observational 
case series 
Adult patients 
with SRSE 
2 Patient 1: 
administration of 
enteral KD, Patient 
2: Initial induction of 
ketosis via 
starvation and then 
enteral 
administration of KD 
Assess the efficacy 
of the KD in treating 
patients with SRSE 
(both in hospital and 
after discharge) 
In patient 1, administration of KD 
resulted in reduced seizure 
frequency with complete cessation 
of seizures by Day 11 post KD 
initiation. In patient 2, initiation of 
ketosis resulted in a reduction of 
seizure frequency and cessation of 
seizures after 8 days of KD.  
AD – Alzheimer’s disease, APOE – Apolipoprotein E, ß-OHB – ß-hydroxybutyrate, CHO – Carbohydrate, GBM – Glioblastoma multiforme, KD – Ketogenic diet, MCI 
– Mild cognitive impairment, OKC – oral ketogenic compound, PD – Parkinson’s disease, SRSE – Severe refractory status epilepticus 
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There were no differences in CSF and cerebral lactate concentrations between the two 
groups. The study had insufficient sample size to draw any conclusions regarding the 
nutritional effects on neurological outcome following TBI.  
Parkinson’s disease 
VaniItallie et al. prospectively investigated the feasibility of a ketogenic diet (KD) in adult 
patients with idiopathic Parkinson’s disease (PD) 211. Seven patients were assessed over 
one month and were required to prepare KDs at home by themselves. Five of the seven 
patients adhered to the diet over the course of the study. The diet was associated with 
improved symptoms of PD (as per the Unified Parkinson’s Disease Rating Scale) however 
there was insufficient power to draw significant conclusions from this finding.  
Status epilepticus  
Nam et al. retrospectively reviewed the effects of an oral KD in patients with severe 
refractory status epilepticus (SRSE) 212. Five patients were reviewed, of which one was an 
adult patient. In this patient there was complete resolution of seizures within one month with 
no significant adverse effects reported, and the patient was discharged home with normal 
neurological function. Strzelczyk et al. investigated the effects of an intravenous and enteral 
ketogenic diet in an adult patient with SRSE 213. Commencement of the KD was associated 
with a resolution of status epilepticus, however there was ongoing myoclonus and the patient 
still had generalised tonic-clonic seizures every 3-4 days. There were no episodes of status 
epilepticus in the 4 months of follow up. Wusthoff et al. reported a case series of two adults 
with SRSE treated with a ketogenic diet 214. The first patient was an adult female with SRSE 
despite 3 months of maximal medical therapy. An enteral ketogenic diet was commenced 
on hospital day 101 and within four days a reduction in seizure frequency was noted; there 
was complete resolution of seizures after 11 days of KD. At the time of discharge, the 
patient’s neurological function improved however did not return to her pre-hospital baseline. 
The second patient was an adult male with SRSE with no clinical response to maximal 
antiepileptic therapy after 18 days. Ketosis was induced on day 18 initially with fasting and 
then an enteral KD. Midazolam was weaned on day 26 and the patient was subsequently 
discharged on antiepileptics and a modified KD. At one year of follow up, only one self-
limiting seizure was reported and he had returned to work.  
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Intracranial neoplasms 
Schwartz et al. investigated whether the oral KD could alter glioma progression in two adult 
male patients with Glioblastoma Multiforme (GBM) 215. Both patients had advanced posterior 
GBM and had already received surgery, radiotherapy and chemotherapy. The first was 
commenced on an oral KD 20 months after his initial diagnosis. He continued the diet for 4 
weeks but subsequently withdrew from the study after serial imaging revealed further 
progression of the tumour. The second patient was enrolled into the study 14 months after 
his initial diagnosis. He was commenced on the oral diet and maintained it for 12 weeks, 
however clinical and radiological assessment at this time point revealed tumour progression 
and he subsequently withdrew from the study. Rieger et al. prospectively investigated 20 
adult patients with recurrent glioblastoma to assess the feasibility of a very-low carbohydrate 
diet as a potential treatment modality in this group, over a 16-week period 216. After 2-3 
weeks, three patients (15%) discontinued the diet due to the impact on their quality of life. 
The remaining 17 patients adhered to the diet over the entire course of the study. Champ et 
al. 217 retrospectively reviewed a case series of 53 patients with GBM, 6 of whom trialled a 
KD during their treatment course. The purpose of the study was to assess the biochemical 
and toxicity profile of the ketogenic diet in this population. The authors reported no significant 
adverse effects related to the diet with no documented episodes of hypoglycaemia or toxicity 
related to the diet. 
Adverse effects and issues related to ketosis 
Poor compliance was associated with the KD due to poor palatability 211, 215. Henderson et 
al. reported a higher rate of diarrhoea in the ketogenic diet group compared to the placebo 
group however this was not discussed in the other studies 208; notably this was specifically 
not mentioned as an adverse outcome in the study by Rieger et al 216 and was retrospectively 
reported as well-tolerated in the study by Champ et al 217.  
Krikorian et al. questioned the long-term feasibility and safety of the diet, particularly with 
respect to adequate nutrient intake. The other concern was regarding the potential for weight 
loss, particularly the effects this may have on elderly patients susceptible to sarcopenia 209.  
There were no reports of hypoglycaemia in patients trialling the KD in any of the studies. 
Thakur et al. reported acidosis as a complication in one of their patients and in the study by 
Wusthoff et al., bicarbonate was supplemented on a daily basis to maintain acid-base 
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balance 201, 214. There were no other reports of metabolic acidosis secondary to ketogenesis. 
Thakur et al. reported two patients developing complications of hypertriglyceridaemia 201.  
6.5   Discussion 
The purpose of this systematic review was to review the evidence pertaining to the use of 
ketogenic therapy in the management of neurological and neurosurgical disorders in adults. 
While ketogenic therapies have been extensively studied in epileptic children, evidence in 
adults is lacking.  Of the papers included, there is significant heterogeneity between the 
studies, including differences in study populations, trial designs, methods of ketosis 
induction and chosen primary end points. The studies included in our review have focussed 
on the role of ketosis in status epilepticus, or in patients with mild cognitive impairment and 
Alzheimer’s disease, brain tumours or traumatic brain injury.  
A number of cellular mechanisms are thought to underlie the neuroprotective activity of 
ketones. Ketones enhance cerebral mitochondrial energy usage by providing enhanced 
energy stores and providing a more efficient source of energy per unit oxygen consumption 
as compared to glucose. Ketones may interfere with glutamate mediated toxicity, possibly 
via attenuation of glutamate-induced reactive oxygen species (ROS) formation. GABA levels 
are enhanced with subsequent increase in GABA mediated inhibition 218, a possible 
explanation for the anti-epileptic effects. ROS species may decrease via a number of 
mechanisms including a reduction in coenzyme Q semiquinone and increased activity of 
glutathione peroxidase activity 59, 219. Apoptosis or programmed cell death plays an important 
role in cellular damage following injury. The ketogenic diet may mitigate apoptosis by 
inhibition of kainic acid-induced accumulation of the protein clusterin, thought to influence 
apoptotic signalling 220. And lastly, carbohydrate restriction itself is neuroprotective via 
various mechanisms including suppression of ROS production, stabilization of intracellular 
calcium and improvements in mitochondrial function. 
Status epilepticus is a serious and an often fatal condition. The use of KD to control status 
epilepticus in adults has been reported in several case reports and one case series, with a 
total of 13 patients (12 treated with an enteral diet, one treated with a parenteral KD) 201, 213, 
214, 221. The underlying diagnoses in these cases included encephalitis, anoxia, 
neurocysticercosis and cortical dysplasia. Patients were generally in status for a number of 
days prior to the initiation of the ketogenic diet as a rescue therapy. Strzelczyk et al published 
the first and only description of emergency induction of an intravenous ketogenic diet 
Systematic Review of the use of ketones in the management of acute and chronic neurological disorders 
79 
utilizing a combination of commercially available TPN solutions 213. They describe the case 
of a 21-year-old female with a history of poorly controlled myoclonic and generalized 
seizures who presented in status epilepticus. The patient was treated for 16 days with 
multiple antiepileptic meds and general anaesthesia with little improvement. The IV KD was 
initiated with commercially available fat emulsion with medium-chain triglycerides; this was 
then converted to enteral feeds several days later. Her seizures gradually improved and 
discharged after 47 days with no further episodes of status after 4 months. Given the lack 
of large studies, it is difficult to draw any conclusion regarding the efficacy of ketosis on 
seizure control during status epilepticus. It is promising however that no significant issues 
were present with regards to safety of ketosis. 
The ketogenic diet may have a role in modifying disease progression in a number of 
neurodegenerative disorders. Much of the pathophysiology of Parkinson’s and Alzheimer’s 
disease relates to mitochondrial dysfunction and ketones may play a neuroprotective role. 
In Parkinson’s disease for example, it is hypothesized that the death of the dopaminergic 
neurons may partly reflect impairment of mitochondrial complex I activity. Ketones may play 
a role by either bypassing complex I and providing an alternative fuel source or enhancing 
mitochondrial function with subsequent improvements in ATP production and 
neuroprotection 62, 83. The VanItallie study confirmed that patients able to tolerate a 
ketogenic diet improved their Unified Parkinson Disease Rating Scale scores with no 
harmful effects 211. Although the study had insufficient power to allow any conclusions on 
the clinical effects of the KD, the data appears promising and certainly invites further study 
into the potential therapeutic effects of ketones in this group of patients.  
In Alzheimer’s disease, the ketogenic diet may be neuroprotective via a number of 
mechanisms. Castellano et al. have shown through nuclear imaging that patients with 
Alzheimer’s disease can have regional brain hypometabolism secondary to impaired 
glucose uptake 222. Subsequently, ketosis may offer an alternative metabolic substrate for 
the brain in this population. Secondly, by improving mitochondrial efficiency, ketones may 
provide protection against the deposition of Amyloid-B 1-42 (AB), which is thought to be 
crucial to the development of this disease 83. This has been observed in transgenic mice 
models of AD where animals fed the ketogenic diet had 25% less soluble AB in their brains 
after only 40 days 85. In humans, there is some evidence that this process may be 
determined by the presence or absence of the APO-4 allele; the presence of which is a risk 
factor for developing AD. Henderson et al found a beneficial effect of the ketone inducing 
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diet only in individuals where the allele was absent 208. Confounding these findings is that 
dietary supplementation of fatty acids itself may improve cognitive function in patients with 
AD. More research is necessary to clarify the importance of various supplements in 
mitigating the ongoing neurodegeneration in patients with AD disease.  
Despite a number of animal studies 72, 74 investigating the benefits of ketone administration 
in a variety of models of acute brain injury, only a single study has been published in 
humans. In Ritter et al.’s study, the intervention group, blood glucose concentration 
remained well controlled, arterial lactate concentrations were lower and plasma ketones 
higher compared to the control standard feeding group 91. Twenty patients were included 
and randomized to either trial feed or standard feeding. In the intervention group, blood 
glucose concentration remained well controlled, arterial lactate concentrations were lower 
and plasma ketones higher compared to the control standard feeding group. Otherwise, 
there was no difference between the groups and they did not report any major side effects. 
Animal studies have suggested that acute brain injury induces rapid changes in cellular 
transporters that favour ketone uptake and metabolism. In a rodent model, Prins et al. found 
that administration of intravenous -hydroxybutyrate after TBI mitigated the reduction in ATP 
availability after injury and an associated reduction in cortical contusion volume 74. Similar 
findings have been observed in a stroke model, where Suzuki et al found a decrease in 
stroke size in a hypoxic animal model treated with -hydroxybutyrate 73.  
Adverse effect profile of ketogenic diets 
In our review, induction of ketosis did not appear to have significant safety or adverse effects 
in the studied populations. Data on the adverse effects of ketone administration are limited 
in the adult population. In the acute setting, effects of parenteral formulations on pH, Na, 
lipids and glucose are likely to predominate. This was confirmed by Hiraide et al who noted 
a significant increase in pH and Na concentrations following the IV administration of a 20% 
solution of NaBHB to severe trauma patients 94. Also of potential concern is the reduction in 
cerebral glucose metabolism and increased cerebral blood flow demonstrated by 
Hasselbalch et al during administration of intravenous BHB 58. The long term consequences 
of this are not known, but may have implications in the short term to patients with traumatic 
brain injury, cerebral oedema or raised intracranial pressure. Some side effects are 
predictable following enteral administration such as dehydration and hypoglycaemia. Others 
are less common and present following prolonged use, including growth retardation, obesity, 
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nutrient deficiency, decreased bone density, hepatic failure, and immune dysfunction. 
Freeman has reported a significant rise in mean blood cholesterol to over 250 mg/dl 
following prolonged intake a of ketogenic diet 99. This in turn may be atherogenic, leading to 
lipid deposition in blood vessels. Finally, an increased incidence in nephrolithiasis in patients 
on the ketogenic diet as well as increases in serum uric acid secondary have been reported 
76, 100. 
Limitations of this systematic review 
This systematic review was limited by the small number of studies and a preponderance of 
case reports and case series. While results from the studies suggest a clinical benefit from 
ketosis, the paucity of well-designed clinical trials creates problems when interpreting the 
data. In many instances it is difficult to definitively prove a causal relationship between 
initiation of ketosis and neurological improvement including cessation of seizure activity. 
There is often a prolonged lag time between initiation of the ketogenic diet and seizure 
cessation (>1 week in 6 out of the 13 patients). Moreover, the studies did not have a 
sufficient sample size and power to show a treatment effect. Furthermore, there is a bias to 
publish positive results and it is not known how many patients failed to respond to treatment. 
Additionally, there are minimal prospective data available on this topic. Of the case reports 
on status epilepticus, 3 deaths were reported during hospitalization, however, the long term 
outcomes of the other patients were not reported.  
6.6 Conclusion 
The evidence for the use of ketogenic diets or induction of ketosis for the management of 
neurological conditions in adults is limited. Although there might be a suggestion of benefit 
in limiting the frequency of seizure episodes in patients with refractory status epilepticus, a 
number of case reports and case series are available, but high quality research is yet to be 
produced. Theoretically, the induction of ketosis is a promising therapeutic tool in the 
management of both acute and chronic neurological and neurosurgical disorders. It is time 
for a well-designed study to be undertaken in adults to determine if the potential benefits 
translate into clinical success. 
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Chapter 7:  Inducing ketogenesis via an enteral formulation in patients 
with acute brain injury: A phase II study 
7.1  Synopsis and citation 
Background: 
Although extensively studied in children, the safety and tolerability of ketone 
supplementation in adults is unclear, particularly in the acute brain injury population.  
Aim: 
To examine the feasibility of inducing ketosis using an enteric ketogenic formulation as 
measured by plasma beta-hydroxybutyrate and acetoacetate concentrations and determine 
its impact on cerebral hemodynamics and metabolic parameters 
Design: 
Prospective interventional Phase II trial of ventilated critically ill patients with acute brain 
injury administered a ketogenic feed over a 6 day period  
Key Findings: 
20 patients were recruited, 5 females and 15 males, 3 with stroke, 2 with subarachnoid 
haemorrhage and 15 with traumatic brain injury. Feeds were well tolerated with 19 patients 
completing study. There was a significant increase in both plasma beta-hydroxybutyrate and 
acetoacetate to 0.61 ± 0.53 mmol/l (p =0.0005) and 0.52 ± 0.40 mmol/l (p<0.0001) over the 
6 day period. Total daily Ketocal® caloric intake was positively correlated with plasma beta-
hydroxybutyrate concentrations (p=0.0011). There was no correlation between cerebral 
hemodynamic indices and plasma ketone concentrations. In 19 patients, there were no 
clinically significant changes in acid/base status over the 6 days with pH remaining within 
normal range. One patient developed a metabolic acidosis and feeds were ceased. No 
severe adverse events were reported. 
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Conclusion: 
In patients with acute brain injury, an enterally administered ketogenic formulation was well 
tolerated and can be safely administered. 
Citation: 
An oral presentation titled “Inducing ketogenesis via an enteral formulation in patients with 
acute brain injury: A phase II study” by H White, M Jones, P Kruger and B Venkatesh. This 
will be presented at the CICM ASM meeting Hobart 2018. (Oral presentation by H White) 
Contributions: 
Hayden White, Peter Kruger, Mark Jones and Balasubramanian Venkatesh made 
substantial contributions to the design, acquisition and analysis of data and writing of 
publication. James Walsham made significant contributions to data analysis and writing of 
publication. All authors approved final version.  
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7.2 Introduction 
Ketogenesis is the process by which ketone bodies (beta-hydroxybutyrate and 
acetoacetate), are produced via fatty acid metabolism. In health, glucose is the brain’s 
primary metabolic substrate. Ketones however, are capable of acting as an alternative fuel 
source, supplying up to 70% of basal cerebral energy requirements 27, 223. Acute brain injury 
(ABI) is a common and catastrophic event leading to significant morbidity and mortality. 
Much of the pathology relates to disruption of the normal cerebral metabolic energy supply 
leading to an inability to maintain cerebral energy requirements 224, 225. Ketones may 
represent an alternative fuel in these instances.  
Ketogenic diets have demonstrated benefit in a wide range of neurological disorders 
including childhood epilepsy, autism, Alzheimer’s disease, migraine, strokes, hypoxic-
ischemic encephalopathy, Parkinson disease, amyotrophic lateral sclerosis, and traumatic 
brain injury (TBI) 91, 168, 208, 211, 226-228. More recent studies have examined the use of 
ketogenic diets in the management of brain tumours based on the finding that as tumour 
cells are more able to utilize glucose, altered glucose metabolism may have anti-tumour 
effects 215.  
The determinants of cerebral ketone concentrations include plasma concentration and 
duration of ketosis 1, 229. We have previously demonstrated in an animal model that infusion 
of a bespoke hypertonic sodium beta-hydroxybutyrate (BHB) intravenous (IV) solution 
produced a rapid increase in both plasma and cerebrospinal fluid (CSF) BHB concentrations 
with no perturbations in metabolic acid-base status 144. However, no commercial intravenous 
formulation of ketones is currently available. The induction of ketosis via the enteral route is 
well established, particularly for the management of refractory epilepsy in children 168, 230. 
The evidence for the administration of enteral ketones to adults with neurological disorders 
however is far less clear with case reports and case series dominating the literature 231, 232.   
Despite evidence suggesting possible benefits to inducing ketosis in neurological disorders, 
there are no published data investigating the safety, feasibility, metabolic and detailed 
cerebral haemodynamic effects of inducing ketosis in adults with acute brain injury (ABI) 
defined as patients diagnosed with acute subarachnoid haemorrhage (SAH), Traumatic 
brain injury (TBI) and strokes or cerebrovascular accidents (CVA). We hypothesized that a 
commercially available enteral ketogenic feeding formulation could produce ketosis, without 
adversely affecting acid-base status or cerebral hemodynamics in patients with ABI. 
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The KABI (Inducing ketogenesis in patients with acute brain injury) study was a Phase II trial 
with the primary aim of examining the feasibility of inducing ketosis using an enteric 
ketogenic formulation as measured by beta-hydroxybutyrate (BHB) and acetoacetate 
(AcAc) concentrations in plasma and CSF. Our secondary aims were to determine the 
impact of a ketogenic diet on the temporal profile in intracranial pressure (ICP) and cerebral 
perfusion pressure (CPP) during administration and to assess tolerability of this formulation 
by studying its impact on metabolic and acid-base parameters.  
7.3 Methods 
Patients  
This single site, prospective, interventional study was conducted over a 12 month period to 
investigate the changes in ketone concentrations in plasma and CSF following acute brain 
injury.  The study setting was a single metropolitan Intensive Care Unit (ICU). Ethics 
approval was granted by the Princess Alexandra Hospital Human Research Ethics 
Committee (HREC/16/QPAH/30). Written informed consent was obtained from the 
participants ‘person responsible’. 
Protocol  
Within 48 hrs of admission to ICU, 20 adult mechanically ventilated critically ill patients with 
ABI (defined as any patient admitted with a diagnosis of an acute stroke, SAH or TBI) and 
expected to survive for a minimum of 72 hours were enrolled. Patients were excluded if < 
18 years of age, pregnant, or suffering from Acute or Chronic liver disease or type I diabetes. 
Following entry into study, the patients were administered the ketogenic formulation (see 
below) via a naso-gastric tube as a continuous infusion. The individual caloric targets were 
determined as per the ICU feeding protocol. Episodes of feed intolerance were managed 
according to the institutional feeding protocol guidelines. The infusion continued for a 
maximum of 6 days or until extubation.  
Feeding formulation  
Patients enrolled into the study received a combination of 2 commercial enteral formulations 
- Ketocal® (Nutricia, Macquarie Park, NSW, Australia) and Protifar® (Nutricia, Macquarie 
Park, NSW, Australia). Ketocal® is a commercially produced ketogenic formulation. The 4:1 
ratio product consists of 8.3% protein, 3.1% CHO and 88.7% fat. It contains a blend of oils 
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(high oleic sunflower, soy, palm oil), milk protein (casein and whey), supplemental amino 
acids, carbohydrate, vitamins, minerals and trace elements. The energy density is 1.5 
kcal/ml consisting of 4 g of fat for every 1 g of protein and carbohydrate. Based on a caloric 
goal of 25-30 kcal/kg/d and protein gal 1.2 g/kg/d the formulation does not deliver adequate 
protein supplementation at target caloric intake; it was therefore combined with an additional 
feed, Protifar®, rich in proteins. Protifar® is a protein supplement containing 2.2 g protein 
(casein and whey) per scoop. Final mixture consisted of Ketocal® which provided 1500 kcal/l 
of energy and 31 g protein per litre, supplemented with 28 g/l of Protifar® providing a total 
protein of 59 g/l. 
Patients were allowed to receive standard enteral feeds (Nutrison® Protein Plus Multifiber) 
(Nutricia, Macquarie Park, NSW, Australia) prior to enrolment or following the end of the 
study period. The use of sedation, analgesia, and other intravenous fluids were administered 
as determined by treating physician. The management of ICP and CPP were as per ICU 
guidelines based on Brain Trauma Foundation 2007 guidelines 233, 234. Glucose containing 
solutions were avoided where possible. 
Physiological Analysis 
Blood and CSF (if external ventricular device (EVD) present) samples were collected at 8 
AM on study days and tested immediately. All clinical observations were recorded hourly for 
the duration of the study. The cerebral hypoperfusion (CHI) and intracranial hypertension 
indices (IHI) were based on hourly ICP and CPP measurements 235. 
The intracranial hypertension index was calculated as follows; 
 = 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑜𝑏𝑠𝑒𝑟𝑣𝑎𝑡𝑖𝑜𝑛𝑠 𝑜𝑓 𝐼𝐶𝑃 > 20 𝑚𝑚𝐻𝑔
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑜𝑏𝑠𝑒𝑟𝑣𝑎𝑡𝑖𝑜𝑛𝑠
 x 100 
The cerebral hypoperfusion index was calculated as follows; 
 = 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑜𝑏𝑠𝑒𝑟𝑣𝑎𝑡𝑖𝑜𝑛𝑠 𝑜𝑓 𝐶𝑃𝑃<50 𝑚𝑚𝐻𝑔
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑜𝑏𝑠𝑒𝑟𝑣𝑎𝑡𝑖𝑜𝑛𝑠
 x 100 
For safety purposes, blood glucose and BHB were monitored with the Optium FreeStyle 
glucose/ketone hand held device (Abbott Diabetes Care Roma, Italy). 
The total daily catecholamine dose (adrenalin and noradrenalin) was recorded in mg per 
day. Insulin infusions were similarly recorded in units per day.  
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Biochemical analyses 
Blood samples were obtained simultaneously for the measurement of plasma ketones (Beta-
hydroxybutyrate (BHB) and acetoacetate (AcAc), glucose and arterial blood gases: (pH, 
PaCO2, bicarbonate (HCO3,), anion gap and lactate), kidney and liver functions. If an EVD 
was present which facilitated CSF drainage and collection, CSF was tested for BHB and 
Acetoacetate concentrations.  
Plasma BHB was measured quantitatively using the Stanbio Laboratory β-Hydroxybutyrate 
LiquiColor Assay Kit (Boerne, TX, USA) on the Beckman DxC800 Unicell (Brea, CA, USA) 
analyser using a spectrophotometric endpoint assay. Specimens were collected in lithium 
heparin tubes (#456083, Greiner Bio-One, Kremsmunster, Austria). The linearity of the 
assay is 0.0-4.0 mmol/l with the coefficient of variation (CV) 3.0% at 0.38 mmol/l and CV 
2.1% at 1.38 mmol/l Plasma AcAc concentrations were determined using an automated 
modification of the original endpoint procedure described by Williamson et al on a Cobas 
Bio centrifugal analyser5 (Roche, Basel, Switzerland). Specimens were collected in lithium 
heparin tubes (#456083, Greiner Bio-One, Kremsmunster, Austria). The linearity of the 
assay is 0.008-1.0 mmol/l (CV 3.6% at 0.003 mmol/l and 2.5% at 0.437 mmol/l). 
Arterial blood gases were measured quantitatively using Siemens RAPIDpoint 500 
(Siemens Healthcare Diagnostics Inc., Frimley, Camberley, UK). 
Statistical analysis 
With 20 included patients there was an 80% power to detect a large (by convention a large 
effect size is given by Cohen as f 2 = 0.35) increase in ketone concentrations over the 6 days 
of follow up assuming a 1-sided 5% level of significance. Changes in ketone concentrations 
over time were described using boxplots. We used linear mixed models to estimate the linear 
change in ketone concentrations. Mixed models were also used to estimate associations 
between ketone concentrations and other variables of interest.  
Safety evaluation 
Regular safety analysis was undertaken by an independent monitor (after every 5 patients). 
The safety assessment of the enteral formulation included continuous monitoring for 
adverse events. Subjects were monitored for nausea or vomiting, constipation and 
diarrhoea, hypoglycaemia and metabolic acidosis. Laboratory tests were performed as 
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described above.  Three safety analyses were performed and no safety concerns were 
identified.  
7.4 Results 
Baseline characteristics 
Twenty patients with ABI were recruited into the study (5 F and 15 M). The admission 
diagnoses included 3 CVA, 2 SAH and 15 with TBI. The median APACHE II score was 21 
(range 10-28). The mean (median, range) GCS at time of enrolment was 3 (median 3, range 
3-6 and 13 (median 13, range 10-15) at ICU discharge. The overall ICU mortality rate was 
20%. 15 patients had ICP monitoring. 4 of which were through an EVD. The mean length of 
time from admission to commencement of ketogenic feed was 33.2 ± 21.4 hours. The clinical 
characteristics and outcome data are summarised in Table 7.1 
Table 7.1 Demographic data of patients with acute brain injury (mean +/- SD) 
Variable CVA (N = 3) SAH (N = 2) TBI (N = 15) Total N = 20) 
Sex 
       Male 
       Female 
    
15 
5 
Age 61 ± 19 64 ± 13 55 ± 21 51 ± 19 
LOS (Hours) 142 ± 45 327 ± 192 237 ± 157 232 ± 150  
ICU Mortality (%)    20 
CVA: cerebrovascular accident; SAH: subarachnoid haemorrhage; TBI: traumatic brain injury; LOS: length of 
stay 
Feeding tolerance 
Total daily nasogastric aspirates (mls per day) were high on day one (404 ± 331 ml/d), by 
day 6 this had decreased to 193 ± 266 ml/day. Total caloric intake varied from 1362 ± 559 
kcal on day 1 to peak at 1705 ± 857 kcal by day 5. 11 patients completed 5-6 days of 
ketogenic feed. 15 patients received other enteral feeding (Nutrison®) the day prior to 
inclusion in the above study.  
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Plasma Ketone profiles  
The mean baseline plasma BHB and AcAc concentrations were 0.24 ± 0.31 mmol/l and 0.19 
± 0.16 mmol/l respectively (Table 7.2) (Figure 7.1 and 7.2).  
Table 7.2 Plasma ketones and glucose profiles over trial period 
 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 
Glucose 8.73 ± 1.95 6.99 ± 0.99 7.07 ± 1.13 6.93 ± 1.01 7.01 ± 1.53 7.50 ± 2.16 
BHB 0.24 ± 0.31 0.45 ± 0.63 0.50 ± 0.51 0.50 ± 0.33 0.65 ± 1.09 0.61 ± 0.53 
Acetoacetate 0.19 ± 0.16 0.31 ± 0.33 0.45 ± 0.30 0.48 ± 0.22 0.49 ± 0.64 0.52 ± 0.40 
All data were expressed as mean ± standard deviation  
BHB: beta-hydroxybutyrate 
 
Figure 7.1 Distribution of acetoacetate by day 
Boxplots show a decrease in glucose from day 1 to day 2 (p=0.0002) then a stabilised glucose for days 3 to 6. 
Mixed models analysis shows a consistent result. Horizontal lines within the boxes show the median, and the 
boxes show interquartile range. Mean represented by ◊ 
There was a significant increase in both plasma BHB and AcAc to 0.61 ± 0.53 mmol/l (p 
=0.0005) and 0.52 ± 0.40 mmol/l (p<0.0001) over the 6 day period. 90% of patients 
increased plasma BHB concentrations from day 1, while 95% increased plasma AcAc 
concentrations. 
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Figure 7.2 Distribution of BHB by day 
Boxplots and mixed model results suggest betahydroxybutyrate (BHB) increased approximately linearly over 
6 days of follow up by 0.08 units per day (P=0.0005). Horizontal lines within the boxes show the median, and 
the boxes show interquartile range. Mean represented by ◊ 
60% patients demonstrated a peak plasma BHB concentration above 0.50 mmol/l and 25% 
above 1.00 mmol/l. There was a significant decrease in mean serum glucose (8.7 ± 1.9 
mmol/l to 7.0 ± 1.0 mmol/l, p=0.0002) from day 1 to day 2 and then stabilised for days 3 to 
6 (mean glucose on day 6 was 7.5 ± 2.6 mmol/l) (Figure 7.3). There was strong evidence of 
a negative association between glucose and plasma acetoacetate (p=0.0034) and BHB 
(p<0.0001). A positive association was noted between daily intravenous catecholamine 
infusions (mg per day) (Figure 7.4) and plasma BHB (p<0.0001) but no association with 
plasma acetoacetate. There was no association between plasma BHB/acetoacetate and 
daily dosage of insulin (p=0.9171) (Figure 7.5). Of patients who received Nutrison® feeds 
(either prior or at the completion of the study) when compared with Ketocal® feeds, there 
was a strong negative association between total daily caloric intake of Nutrison® and plasma 
BHB concentration (p<0.0001) while total daily Ketocal® caloric intake was associated with 
a positive correlation with plasma BHB concentrations (p=0.0011) (Figure 7.6). 
CSF was obtained from 4 patients with EVD’s in place. CSF BHB and AcAc concentrations 
ranged from 0.05 – 0.68 mmol/l and 0.02 – 0.16 mmol/l although 50% of specimens were 
contaminated with blood. 
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Figure 7.3 Distribution of glucose by day 
Boxplots show a decrease in glucose from day 1 to day 2 (p=0.0002) then a stabilised glucose for days 3 to 6. 
Mixed models analysis shows a consistent result. Horizontal lines within the boxes show the median, and the 
boxes show interquartile range. Mean represented by ◊ 
 
Figure 7.4 Comparison of daily plasma BHB concentration with total daily intravenous 
catecholamine infusion (mg/day). 
BHB betahydroxybutyrate                                                                                                                                                 
Catecholamine infusion includes noradrenalin and adrenalin and represented as mg of catecholamine 
delivered per day 
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Figure 7.5 Comparison of daily plasma BHB concentration with total daily intravenous insulin 
infusion (units/day) 
BHB – betahydroxybutyrate 
Insulin infusion represented as units of insulin delivered per day  
 
 
Figure 7.6 Daily plasma BHB concentration compared with total daily calories from Ketocal 
(kcal/day) 
BHB – betahydroxybutyrate 
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Acid-base status and other biochemical analysis 
In 19 patients, there were no clinically significant changes in acid/base status over the 6 
days. The mean blood pH increased from 7.39 ±0.04 to 7.45 ±0.04 over the first 3 days and 
then remained within the normal range until day 6 (pH 7.45 ±0.06) (Figure 7.7).  
 
Figure 7.7 Distribution of pH by day 
Boxplots show an increasing pH from day 1 to day 3 (p = 0.0004) then a stabilised pH for days 4 to 6. Mixed 
models analysis shows a consistent result. Horizontal lines within the boxes show the median, and the boxes 
show interquartile range. Mean represented by ◊ 
Serum bicarbonate concentrations remained stable during the study period ranging from 23 
± 3 mmol/l on day one to 24 ±3 mmol/l by day 6 (p=0.26). Lactate was 1.4 ± 0.8 mmol/l on 
day 1 but decreased by day 2 and remained below 1.0 mmol/l for the rest of study period. 
One patient however, developed a metabolic acidosis with a peak anion gap of 20 mmol/l 
and BHB of 4.0 mmol/l (see below). Renal function remained within the normal range with a 
steady decrease in serum creatinine concentrations. Serum alanine transferase (ALT) and 
aspartate transferase (AST) concentrations increased over the period as did gamma-
glutamyl transferase and alkaline phosphatase concentrations. The biochemical 
characteristics over the course of the study are summarised in Table 7.3.  
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Table 7.3 Clinical and biochemical observations measured daily over the trial period 
 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 
pH 7.39 ± 0.04 7.42 ± 0.03 7.45 ± 0.04 7.44 ± 0.05 7.44 ± 0.07 7.45 ± 0.06 
pCO2 39.00 ± 3.88 37.55 ± 4.30 36.42 ± 5.31 38.00 ± 4.50 37.14 ± 5.71 36.25 ± 6.11 
pO2 92.60 ± 22.14 89.80 ± 21.88 83.32 ± 21.79 79.93 ± 23.34 79.43 ± 29.01 84.00 ± 25.19 
Bicarbonate 23.45 ± 2.74 23.95 ± 2.86 24.84 ± 2.75 25.63 ± 3.70 24.43 ± 3.11 24.33 ± 3.45 
Anion Gap 7.35 ± 2.81 7.85 ± 3.38 8.05 ± 3.12 8.25 ± 3.32 9.50 ± 3.16 10.00 ± 3.07 
Lactate 1.45 ± 0.82 0.91 ± 0.24 0.98 ± 0.23 0.90 ± 0.29 0.89 ± 0.33 0.87 ± 0.25 
AST 48.05 ± 28.7 45.30 ± 28.71 49.35 ± 27.12 58.44 ± 32.66 80.71 ± 94.46 75.00 ± 50.28 
ALT 49.20 ± 74.78 39.20 ± 48.16 41.50 ± 41.21 52.94 ± 42.58 68.57± 69.13 73.46 ± 58.59 
GGT 37.80 ± 25.34 42.15 ± 24.08 57.85 ± 40.60 96.50 ± 58.33 120.36±95.23 131.85±100.37 
ALP 52.50 ± 15.39 57.45 ± 15.74 65.20 ± 28.73 78.63 ± 39.18 91.14 ± 52.31 94.00 ± 50.17 
LDH 284.75±93.71 274.65±79.37 294.65±28.73 336.88±104.33 395.43±136.29 421.00±139.61 
Bilirubin 13.90 ± 4.85 12.70 ± 5.40 12.95 ± 4.67 13.38 ± 5.45 14.00 ± 5.79 15.46 ± 5.53 
Sodium 141.50 ± 5.39 143.25 ± 5.07 142.15 ± 4.74 142.69 ± 5.53 143.14 ± 6.18 142.38 ± 6.19 
Potassium 3.88 ± 0.32 3.77 ± 0.32 3.69 ± 0.39 3.79 ± 0.30 3.70 ± 0.34 3.62 ± 0.23 
Chloride 111.60 ± 6.33 111.65 ± 5.34 109.55 ± 5.94 109.63 ± 6.87 109.71 ± 6.49 108.69 ± 7.70 
Urea 6.25 ± 5.12 6.03 ± 4.87 6.27 ± 4.49 8.37 ± 10.13 9.27 ± 10.38 9.08 ± 9.97 
Creatinine 80.00 ± 35.06 70.40 ± 29.25 67.35 ± 20.06 63.88 ± 11.52 61.29 ± 12.39 59.77 ± 11.84 
All data were expressed as mean ± standard deviation 
AST: Aspartate aminotransferase; ALT: Alanine Aminotransferase; GGT: Gamma glutamyl transferase; ALP: 
Alkaline phosphatase; LDH: Lactate dehydrogenase 
Cerebral hemodynamic indices 
The mean peak ICP measurement decreased from 20 ± 6 mmHg on day 1 to 18 ± 5 mmHg 
(p=0.26) on day 6. The mean lowest CPP measurement increased from 55 ± 9 mmHg on 
day 1 to 57 ± 7 mmHg (p=0.073) on day 6. Neither change was statistically significant. The 
ICH and CPP indices were 12% ± 18% and 3% ± 7% respectively on admission and 2% ± 
2% and 2% ± 4% on discharge (Figure 7.8). There was no correlation between ICH/CPP 
index and plasma ketone concentrations. 15 patients required an intravenous 
catecholamine infusion at some time during the study period to maintain CPP. 10 patients 
required hyperosmolar therapy to manage intracranial hypertension. The mean period for 
Inducing ketogenesis via an enteral formulation in patients with acute brain injury: A phase II study 
95 
which hyperosmolar therapy was necessary was 43.5 ± 74.3 hours although the range was 
wide (0 – 280 hours). 
 
Figure 7.8 Daily ICH index compared with daily CPP index 
ICH index – intracranial hypertension index. CPP index – cerebral hypoperfusion index 
(see text for calculation) 
Adverse effects 
The ketocal feeds were well tolerated (Table 7.4). Only 8 episodes of vomiting and diarrhoea 
were recorded during the study period. No episodes of hypoglycaemia or seizures were 
reported during study period. 
Table 7.4 Adverse events 
 Number of patients 
experiencing 1 or more event 
Vomiting and diarrhoea 8 
Hypoglycaemia 0 
Seizures 0 
Metabolic academia 1 
Increase in hepatocellular or 
cholestatic liver enzymes from 
baseline 
12 
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Feeds were prematurely ceased on one patient who developed a metabolic acidemia while 
on ketogenic diet in the setting of severe sepsis, malnutrition and vasopressor requirements. 
The ketogenic feed was stopped and the anion gap and BHB returned to normal within 36 
hours.  All other patients completed the study as per protocol. As noted above, there was 
an increase in the mean concentration of both hepatocellular and cholestatic liver enzymes 
during the study period. No severe adverse events were reported. 
7.5 Discussion 
This phase II study of ketogenic feeds in 20 ventilated ICU patients with acute brain injury, 
demonstrates that an enterally administered ketogenic formulation consistently increased 
plasma BHB and acetoacetate concentrations, above both baseline and the normal, non-
fasting ranges. This formulation was associated with an improvement in glucose control, 
was well tolerated with few gastro-intestinal side effects and with no adverse impact on 
intracranial hemodynamics or acid-base parameters in 19 out of the 20 patients. An increase 
in several hepatocellular and cholestatic enzymes was noted although the clinical 
significance and causation of this is not clear. To our knowledge, this represents the most 
comprehensive study of ketone diets in patient with ABI to date.  
Despite the lack of clinical studies, a body of experimental work supporting the benefits of 
ketone supplementation as an alternative source of fuel in acute and chronic brain disease 
exists 51, 130. BHB is more energy efficient then glucose and increases ATP production via 
an increase in citric acid cycle intermediates with a 16-fold elevation in acetyl CoA content 
52, 53. Ketones reduce formation of reactive oxidant species and protect against glutamate 
mediated apoptosis and necrosis 54-56. They also improve cerebral blood flow by up to 39% 
56. During times of oxidative stress, the ability of the brain to utilize glucose may become 
compromised and ketones may be preferentially taken up, an effect which may be 
augmented by the external supply of ketones 75. 
Despite demonstrating a significant increase in plasma BHB concentrations to 0.61 ± 0.53 
mmol/l, it is unclear whether this concentration is sufficient to provide significant cerebral 
metabolic substrate. Gilbert et al demonstrated a significant correlation (r=0.471 p = 0.007) 
between plasma BHB concentrations and seizure control in children on a ketogenic diet with 
a cut off of 4 mmol/l the most effective 87. This was supported by Cahill et al who suggested 
a therapeutic plasma BHB range of 3-5 mmol/l necessary for clinical benefit 143. However, 
other authors suggest that the clinical benefit of targeting a specific BHB plasma 
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concentration is controversial 196. In children with acyl CoA dehydrogenase deficiency, blood 
BHB concentrations of 0.19-0.36 mmol/l produced a therapeutic response 86. Furthermore, 
a study on the benefits of ketone supplementation in cognitively impaired adults 
demonstrated an improvement in cognitive function with a peak plasma BHB concentration 
of only 0.68 mmol/l 97. Ketone neuroprotection in various CNS injury animal models seems 
to demonstrate benefit across a broad spectrum of plasma BHB concentrations 73, 80, 236. 
Further study is required to clarify the optimum plasma ketone concentrations in humans.  
A major concern of administering exogenous ketones is the induction of a metabolic 
acidosis. In our study, there was no evidence of perturbations in pH, plasma bicarbonate, 
lactate or the anion gap in 95% of the study population. As noted, one patient developed a 
metabolic acidemia during the trial, although it was in the context of severe sepsis and high 
vasopressor requirements. These findings are consistent with published data from a recent 
study of 20 obese patients placed on a low calorie ketogenic diet 237. These results are also 
in accord with those reported in a study by our group where rats were administered an 
intravenous ketone formulation over a 6 hour period 144.  
A consistent finding in studies investigating the exogenous administration of ketones is the 
improvement in glucose control 91, 237. Our study noted a significant initial decrease in 
glucose from day one and this improvement was sustained throughout the study period with 
no documented episodes of hypoglycaemia. Evidence suggests that during times of injury, 
cerebral metabolism switches to favouring ketones, as glucose may no longer be sufficient 
during high energy requirements 61, 224, 225. High glucose concentrations have persistently 
been associated with poor outcome in critically ill patients with TBI as ischemic injury leads 
to a limited substrate supply and metabolism which is exacerbated by glucose leading to 
lactate accumulation and brain damage 133, 238.  
Our study had a number of strengths. It is the most comprehensive study of a ketogenic 
feed in patients with ABI which included the systematic collection of data with detailed 
plasma biochemical and acid-base profiling and the reporting of metabolic outcomes and 
cerebral hemodynamic indices. A thorough safety assessment was undertaken with 
continuous monitoring for adverse events. The majority of patients completed their feeding 
protocol so that the primary aim of assessing the impact of a ketogenic feed on plasma 
ketone concentrations was successful. The only other published work investigating 
ketogenic diets in the TBI population was from a pilot study by Ritter et al in 1996 91. It was 
a proof of principle study, which examined the effects of a ketogenic diet consisting of 75% 
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lipid and 25% protein on biochemical markers of metabolism in patients with TBI. Only 8 
patients in the experimental arm completed at least 5 days of the study. The authors were 
able to demonstrate better glucose control and significantly higher plasma BHB 
concentrations in the experimental group although there was no difference in neurological 
outcomes at 3 months.   
Our study has several limitations. The limited number of EVD’s prevented an assessment 
of the impact of the ketogenic feed on CSF ketone concentrations. Secondly, as the study 
was not powered to look at clinical outcomes, our measure of outcome was limited to GCS 
on discharge from ICU. Longer outcomes involving more detailed clinical assessment would 
be desirable in future studies. And lastly, we did not address the question of the optimal 
plasma concentration of ketones for clinical benefit.  
A number of questions still remain. Foremost is that although ketone concentrations were 
significantly increased as compared to patients fed a normal diet, it is unclear whether the 
concentrations reached are sufficient to improve cerebral energetics. Further studies are 
necessary to determine; the optimal concentration of ketones necessary to impact on 
cerebral energetics, the best means of inducing ketosis and the overall impact on outcome. 
7.6 Conclusion 
In conclusion, in patients with acute brain injury, an enterally administered ketogenic 
formulation was well tolerated and can be safely administered. 
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Chapter 8:  Conclusions and Future Directions 
The work presented in this thesis provides further evidence to the growing body of 
knowledge that exists regarding the role of ketones in cerebral cellular energetics in patients 
with neurological dysfunction. The synthesis of basic science research and results from both 
animal and human research provide compelling evidence to support ongoing investigation 
into potential treatments in a group of patients which have traditionally suffered from a lack 
of management options. Traditionally viewed as ‘metabolisms ugly duckling’, because of the 
association with DKA, this work has attempted to demonstrate the physiological and clinical 
importance of ketones.  
Although it has been known for over 100 years that starvation states are associated with 
improved seizure control and that this might be due to an increase in blood ketone 
concentrations, detailed research into the mechanisms and possible benefits of 
administering exogenous ketones has only occurred in the past few decades.  This was 
despite the 1928 paper which appeared in NEJM entitled “Ketogenic diet in the treatment of 
epilepsy’ 239. However, researchers at John’s Hopkins continued to advocate for the 
administration of these diets to children with refractory epilepsy and eventually the benefits 
of the ketogenic diet were demonstrated in two randomized controlled trials. A study of 145 
children with poorly controlled epilepsy published in the Lancet Neurology, demonstrated 
that a ketogenic diet was capable of; significantly reducing seizure frequency compared to 
controls, that it was equally effective in both symptomatic generalised or symptomatic focal 
syndromes and was tolerated for extended periods with most frequent side-effects reported 
at 3-month review being constipation, vomiting, lack of energy, and hunger 168.  
However, despite the evidence that ketones supplementation was beneficial in the paediatric 
epilepsy population, adult research remained elusive. Certainly there was encouraging data 
from animal and basic science research that suggested a potential role for exogenous 
administered ketones in the management of acute and chronic neurological diseases which 
may result from energy deficits. The translation of this basic science to treatments for adult 
humans however has been a slow process.  
Our initial goal was to produce an intravenous ketone containing solution. The reasons for 
this was that by administering ketones intravenously, we could be confident that the drug 
would enter the plasma at a controlled concentration and be available to enter the CSF. We 
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could also investigate the effects of dose in a predictable way. Hypertonic saline was chosen 
as it has largely replaced mannitol as the treatment of choice for intracranial hypertension 
and could theoretically improve ICP/CPP and correct cerebral energy deficits 
simultaneously. The data from our animal model was encouraging and confirmed that as 
hypothesized, at least in the concentration range we investigated, plasma, CSF and brain 
ketone concentrations were dependent on IV concentration 144. However, producing an IV 
ketone formulation for humans proved more complicated and expensive than anticipated 
and once it became clear that the costs would be prohibitory, we abandoned this route of 
administration and began searching for a less expensive and more feasible alternative.   
We therefore turned our attention to enteral preparations. Ketogenic diets have been 
examined in a wide range of neurological disorders including autism, Alzheimer’s disease, 
migraine, epilepsy, hypoxic-ischemic encephalopathy, Parkinson disease, amyotrophic 
lateral sclerosis, and traumatic brain injury 91, 165, 208, 210. More recent studies have examined 
the use of these diets in the management of brain tumours based on the fact that altered 
glucose metabolism may have anti-tumour effects.  A number of “ketogenic diets” have been 
described including: the traditional ‘classic’ ketogenic diet, the medium-chain triglyceride 
(MCT) diet, the modified Atkins diet (MAD) and the low glycemic index treatment (LGIT). 
However, it was unclear as to which diet would be the most ketogenic or appropriate in 
acutely ill ABI population. Furthermore, it was unclear what target concentration of BHB to 
aim for. This has not been well studied although there are some reports that concentrations 
closer to 4 mmol/l were necessary to improve cerebral energetics 52, 143.  
There was very little evidence from the adult literature to guide our formulation. The only 
study to date looking at the effects of a ketogenic diet on TBI was conducted by Ritter et al 
in 1996 91. They were able to demonstrate better glucose control in the experimental group. 
Although the BHB concentrations were significantly higher in the intervention group, the 
maximum concentration was still under 0.6 mmol/l.   
We therefore embarked on a number of investigations and reviews to further inform our 
study into the cerebral energy metabolism in ABI patients. As there was no data examining 
ketone concentrations in ABI patients, we undertook an observational study examining 
baseline ketone concentrations in this population 89. We measured ketone in plasma and 
CSF of 38 patients with CVA's, SAH or traumatic brain injury and found that aside from a 
small increase in ketones on admission, the concentrations remained low during their 
hospital stay. We also performed a systematic review of all studies in adults reporting the 
Conclusions and Future Directions 
101 
use of ketones to treat neurological disorders (acute or chronic) and found that although 
there appears to be evidence to support the role of ketones in these disorders, the evidence 
is of poor quality and relies largely on case reports/series 232. Furthermore, there was no 
evidence supporting a specific plasma ketone concentration in adults.  
As ketones are not the only potential energy substrate that may augment cerebral 
metabolism, we undertook a review of other substances including glucose, NEFA, lactate, 
BCAA and anaplerotic molecules including triheptanoin and found again, that the evidence 
was of poor quality although research into lactate supplementation was encouraging 240. We 
also discussed the challenges in developing new fuel substrates for the injured brain. Our 
conclusions were however that ketones supplementation still represents the best option for 
improving cerebral energetics and should be studied further. We therefore set out to design 
a phase II interventional study to look at a commercially available ketogenic feed, Ketocal in 
the adult ABI population. This formulation has been available for many years but largely 
utilized in the paediatric population.  
Our study consisted of 20 adult patients with severe ABI managed in a tertiary ICU. Although 
Ketocal was utilized as our source of calories, the formulation does not provide the 
necessary protein content required for an adult critically ill patient. The formulation was 
therefore modified by adding extra protein. Patients included in the study were fed the 
ketone formulation for a maximum of 6 days. From this study we were able to determine 
that; 1. the formulation was successful in increasing ketone concentrations, 2. the formula 
was well tolerated and there were no issues with delivery, 3. that no major metabolic 
abnormalities were detected especially changes in acid/base status and 4. there was no 
adverse impact on intracranial hemodynamics. Disappointingly, BHB concentrations peaked 
at approximately 0.6 mmol/l which is lower than we predicted but the clinical significance of 
this is not known.  
In summary, the body of work from this thesis consists of; 
1. A literature review of ketone physiology and potential clinical applications 
2. An animal study demonstrating the proof of principle of an intravenous ketone 
formulation 
3. An observational study (n=38 patients) documenting the plasma concentrations of 
ketones in patients with ABI 
4. A literature review of the novel substrates for the injured brain 
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5. A clinical trial (n=20 patients) examining serial concentrations of plasma ketones in 
patients with ABI who are administered a ketone diet and their safety and feasibility 
6. A systematic review of the trials of ketone supplementation in acute and chronic 
neurological states. 
Our findings include; 
1. Ketones are a potential energy substrate for the brain 
2. We have been able to demonstrate that an intravenous ketone formulation is feasible 
and safe in animal models. However, the bench to bedside translation has been 
limited by costs and logistics 
3. We have demonstrated that in an observational study of patients with acute brain 
injury on conventional feeds, plasma concentrations of ketones remain low 
4. Although other potential cerebral energy substrates have been investigated, ketones 
appear to have the strongest evidence supporting their use 
5. Although there is strong evidence for ketone supplementation in childhood epilepsy, 
evidence for the use in adults with acute and chronic neurological disease is limited 
to case series and small RCTs 
6. We have demonstrated in a prospective interventional study that an enterally 
administered ketogenic formulation was well tolerated and can be safely administered 
Gaps in our knowledge 
There remain a number of gaps in our knowledge regarding the optimal use of ketones in 
acute and chronic brain injury.  
• Foremost is mode of administration and dosing of ketone supplementation.  
• No studies exist demonstrating the optimum plasma concentration. During starvation, 
ketone levels may rise to 7 mmol/l. As noted in chapter 7, significant disagreement 
exists between authors with some supporting a therapeutic range of 3-5 mmol/l while 
others have noted improvements with plasma concentrations of less the 1 mmol/l. 
Secondly, although ketosis may be induced by a number of enteral formulations, their 
ability to consistently raise plasma ketone concentrations in adults is limited. Although 
an intravenous formulation would be the most likely to provide a rapid and sustained 
increase in plasma ketone concentrations, no such formulation is available and as 
previously noted, is unlikely in the near future. We therefore require an enteral 
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formulation with more predictable pharmacokinetics. It appears that ketone esters 
have the potential to provide the consistency needed and is explored further below in 
“Future directions”.  
• Thirdly, the optimum duration of ketone supplementation is not known. Although in 
the acute setting, periods of up to 2 weeks are described, no clear evidence exists to 
guide duration. In patients with chronic neurological dysfunction including 
Alzheimer’s, ketogenic diets have been continued for up to 90 days.  
• Although the adverse complications of inducing ketosis has been extensively studied 
in the epileptic population on long term supplementation, little is known of the acute 
effects in the ABI population. Specifically, on intracranial hemodynamics. In our study 
in chapter 7, we failed to demonstrate any significant adverse impact on ICP and CPP 
but our study was limited by the small numbers and short follow ups. A future study 
with the ability to perform cerebral microdialysis may be better able to examine the 
impact of ketosis on cerebral metabolites. Furthermore, studies with larger numbers 
and longer clinical outcomes are required to adequately address the long term impact 
of ketone supplementation. 
• There are no studies examining the term effects of ongoing ketone supplementation 
in the rehabilitation setting. However, as small studies in patients with chronic 
cognitive dysfunction have demonstrated improved functional outcomes following 
ketogenic diets this is a potential area for further research.  
Future directions 
Through this series of studies and reviews, we have been able to determine that exogenous 
ketones are a potential alternative source for cerebral energy supplementation in the injured 
brain. However, the means of administering and increasing plasma levels to theoretically 
beneficial concentrations is still elusive given the fact that an IV formulation is currently not 
feasible. There is however ongoing research in this field looking at other enteral formulations 
which may prove more ketogenic. These include ketone esters.  
Ketone esters  
As noted previously, established methods for inducing ketosis via the oral route consist of 
either adherence to a ketogenic diet or regular ingestion of medium chain triglycerides. 
These diets are generally poorly tolerated, associated with atherogenic lipids and relatively 
ineffective at raising the BHB concentrations in adults much higher than 0.5 mmol/l 241, 242. 
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Furthermore, the efficacy of these diets is dependent on the depletion of CHO from hepatic 
and muscle stores with a subsequent increase in FFA and thus ketone concentrations 243. 
This process takes time and therefore ketone concentrations may not rise for a number of 
hours. Given that evidence suggests higher blood concentrations of BHB are more effective, 
researchers have attempted to examine more efficient methods of increasing plasma ketone 
concentrations.   
One such approach is the use of the ketone monoester (R)-3-hydroxybutyl (R)-3-
hydroxybutyrate to elevate blood ketone concentrations. Following ingestion, the ketone 
monoester undergoes complete hydrolysis into D-b-hydroxybutyrate and R-1,3-butanediol) 
by carboxylesterases and esterases found within the gastrointestinal tract, blood, liver and 
other tissues 244. R-1,3-butanediol is subsequently metabolized to D-b-hydroxybutyrate and 
acetoacetate in the liver 245. 
Significant differences exist between ketosis induced by starvation or high-fat diet and that 
resulting from the ingestion of ketone esters. Ketone bodies are endogenously produced in 
the liver from circulating free fatty acids (FFA) from adipolysis. Ketone esters in contrast are 
cleaved in the gut and are absorbed through the gut epithelium. Raised concentrations of 
ketone bodies inhibit further production of FFA. The subsequent metabolic fate of entering 
the TCA however, is the same.   
Several recent publications have examined the safety and efficacy of a ketone monoester 
produced by the researcher Kieran Clarke from Oxford 147, 193. An initial toxicology study 
looking at the administration of KM for 28 days to rats noted a significant decrease in oral 
intake and weight, but no other significant changes, supporting the safety of KM. A 
subsequent study examined the kinetics, safety and tolerability of KM in 54 healthy adult 
subjects. Both single and multiple doses at varying concentrations (140, 357, or 714 mg/kg 
body weight) were examined. Maximum plasma concentrations of ketones were noted within 
1–2 h, reaching 3.30 mmol/l and 1.19 mmol/l for beta-hydroxybutyrate and acetoacetate, 
respectively. The ketone monoester was subsequently administered at 140, 357, and 714 
mg/kg body weight, three times daily, over 5 days. At the highest dose, BHB concentrations 
did not exceed 5.5 mmol/l. These patients did however experience significant 
gastrointestinal side effects, although this was believed to reflect the high quantities of milk 
ingested as the ketone monoester is administered in a milkshake.   
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A number of future areas of study therefore present themselves. A larger phase II study 
should be undertaken to investigate the limitations of the current research. The choice of 
potential ketogenic supplement needs to be determined but ketone esters, by providing a 
more stable plasma ketone concentration would provide a good starting point. Future studies 
would need to include a number of endpoints not previously investigated including cerebral 
biomarkers. Cerebral biomarkers including S100 and Neuron-specific enolase are markers 
of cerebral injury although clinical applications are still in early phase. Other significant 
endpoints would include detailed evaluation of cerebral hemodynamics and long term 
clinical outcomes, both cognitive and morbidity/mortality. The results of this detailed study 
could then be used to inform the design of a randomized controlled study with the main aim 
of determining whether ketone supplementation leads to an improvement in clinical 
outcomes of patients suffering from TBI.  
In conclusion, investigations into the role of ketones in patients with brain injury remains in 
its infancy. Certainly, the scientific plausibility, animal studies and small human intervention 
studies are encouraging and justify pursuing a more rigorous research agenda into this 
fascinating molecule. Many unanswered questions remain including the most beneficial 
dose, plasma concentration, formulation and route of administration. On a more fundamental 
level, the interaction between ketones, glucose and other potential cerebral substrates 
including lactate require more vigorous investigation. Hopefully our research will lead to a 
greater awareness of this group of molecules, once thought of as a waste product of fat 
metabolism. 
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